var title_f34_37_35408="Alternate site testing PI";
var content_f34_37_35408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Other places to test your blood sugar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows how you can test your blood sugar in places other than your fingertips. You might need to gently massage the skin to get a large enough drop of blood. Do not use other places if you think your blood sugar is low.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35408=[""].join("\n");
var outline_f34_37_35408=null;
var title_f34_37_35409="Subchorionic hematoma";
var content_f34_37_35409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distinction between subchorionic hematoma and unfused amnion in patient with vaginal bleeding at 13 weeks' gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal sagittal sonogram of uterus reveals subchorionic hematoma (H) extending posteriorly around chorion (arrows) and lifting edge of anterior placenta (P). Appearance should not be confused with that of unfused amnion. Amnion is the thin membrane continuous along anterior placental edge, but limited by umbilical cord insertion; subchorionic bleeding leads to edge of placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35409=[""].join("\n");
var outline_f34_37_35409=null;
var title_f34_37_35410="Dibucaine: Drug information";
var content_f34_37_35410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"24\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dibucaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/23/2420?source=see_link\">",
"    see \"Dibucaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/58/16290?source=see_link\">",
"    see \"Dibucaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nupercainal&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local pain (local anesthetic): Topical: Apply gently to the affected areas; no more than 30 g for adults or 7.5 g for children should be used in any 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F159199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/58/16290?source=see_link\">",
"      see \"Dibucaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children: Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 1% [10 mg/g] (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nupercainal&reg;: 1% [10 mg/g] (30 g, 60 g) [contains sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fast, temporary relief of pain and itching due to hemorrhoids, minor burns",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, contact dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amide-type anesthetics, ophthalmic use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9775239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methhemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to  cover the skin following application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dibucaine is not absorbed systemically following topical administration on intact skin. Systemic absorption would be required in order for dibucaine to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F159188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported; however, topical administration is probably compatible.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7281364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Dibucaine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.35 g): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Dibucaine Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Nupercainal Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.4 g): $5.15",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Faktu (EC, PE);",
"     </li>",
"     <li>",
"      Nupercainal (BR, GR, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor through intact skin; well absorbed through mucous membranes and excoriated skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8894 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35410=[""].join("\n");
var outline_f34_37_35410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159203\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159195\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159199\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159196\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159183\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159170\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159184\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159201\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159187\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775239\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299181\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207761\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159188\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7281364\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875316\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159173\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159186\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8894|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/23/2420?source=related_link\">",
"      Dibucaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/58/16290?source=related_link\">",
"      Dibucaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_37_35411="Common hepatic duct mass seen on cholangiography";
var content_f34_37_35411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common hepatic duct mass seen on cholangiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing a filling defect at the bifurcation of the common hepatic duct due to a tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35411=[""].join("\n");
var outline_f34_37_35411=null;
var title_f34_37_35412="Lymphocyte subset anal I";
var content_f34_37_35412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Lymphocyte subset analysis by flow cytometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 380px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow cytometry profile of normal peripheral blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35412=[""].join("\n");
var outline_f34_37_35412=null;
var title_f34_37_35413="Right lung atelectasis";
var content_f34_37_35413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete atelectasis of the right lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complete atelectasis of the right lung due to a tuberculous stricture in the right main stem bronchus. There is complete opacification of the right hemithorax with marked cardiomediastinal shift to the right side. As a result, the cardiac silhouette is obscured by the collapsed lung. The left lung is hyperexpanded and herniates anteriorly across the midline into the right hemithorax. The aortic arch imprint is clearly visible in the lower trachea (arrow) and should not be mistaken for tracheal stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35413=[""].join("\n");
var outline_f34_37_35413=null;
var title_f34_37_35414="Thiotepa: Drug information";
var content_f34_37_35414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thiotepa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/12/35012?source=see_link\">",
"    see \"Thiotepa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/42/27302?source=see_link\">",
"    see \"Thiotepa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bladder cancer:",
"     </b>",
"     Intravesical: 60 mg in 30-60 mL NS retained for 2 hours once weekly for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ovarian, breast cancer:",
"     </b>",
"     I.V.: 0.3-0.4 mg/kg by rapid I.V. administration every 1-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Effusions:",
"     </b>",
"     Intracavitary: 0.6-0.8 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Leptomeningeal metastases (unlabeled use):",
"     </b>",
"     Intrathecal: 10 mg twice a week for 4 weeks, then (if CSF cytology is negative) weekly for 4 weeks, then monthly for 4 doses (NCCN CNS cancer guidelines v.1.2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HSCT for CNS malignancy (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days beginning 9 days prior to transplant (Soussain, 2008)",
"     <b>",
"      or",
"     </b>",
"     150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours for 6 doses, followed by stem cell reinfusion 96 hours after completion of thiotepa (Abrey, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10245670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/42/27302?source=see_link\">",
"      see \"Thiotepa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HSCT for CNS malignancy (unlabeled use; combination chemotherapy):",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days beginning 8 days prior to transplant (Gilheeney, 2010)",
"     <b>",
"      or",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days beginning 5 days prior to transplant (Dunkel, 2010; Grodman, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F227172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution, reduced dose may be warranted. Use may be contraindicated with existing renal impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10245671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution, reduced dose may be warranted. Use may be contraindicated with existing hepatic impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F10245672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Use may be contraindicated with pre-existing marrow damage and should be limited to cases where benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     WBC &le;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Platelets &le;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer as a rapid injection. Infusion times may be longer for high-dose (unlabeled use) treatment; refer to specific protocols",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravesical instillation: Instill directly into the bladder and retain for 2 hours; patient should be repositioned every 15-30 minutes for maximal exposure",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F227210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amikacin, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, ifosfamide, imipenem/cilastatin, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, mitomycin, mitoxantrone, morphine, nalbuphine, ofloxacin, ondansetron, paclitaxel, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, streptozocin, teniposide, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible",
"     </b>",
"     : Cisplatin, filgrastim, minocycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial papillary bladder cancer; palliative treatment of adenocarcinoma of breast or ovary; controlling intracavitary effusions caused by metastatic tumors",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intrathecal treatment of leptomeningeal metastases",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thiotepa may be confused with thioguanine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, contact dermatitis, depigmentation (with topical treatment), dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, spermatogenesis inhibition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, epistaxis, laryngeal edema, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactic shock, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent, postmarketing, and/or case reports: Acute myeloid leukemia (AML), chemical cystitis (bladder instillation), hemorrhagic cystitis (bladder instillation), myelodysplastic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thiotepa or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     May be contraindicated in certain circumstances of hepatic, renal, and/or bone marrow failure; evaluate on an individual basis as lower dose treatment (with close monitoring) may still be appropriate if the potential benefit outweighs the risks",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fertility effects: May be mutagenic and teratogenic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelosuppression: Myelosuppression may commonly occur; use with caution in patients with bone marrow damage, dosage reduction recommended. Use may be contraindicated with existing marrow damage and should be limited to cases where benefit outweighs risk. Monitor for infection or bleeding. Myelosuppression has also been reported with intravesicular administration (due to systemic absorption).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Potentially carcinogenic; myelodysplastic syndrome and acute myeloid leukemia (AML) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction recommended. Use may be contraindicated with existing hepatic impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended. Use may be contraindicated with existing renal impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only. Delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Strong) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F227166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3881813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. There  are no adequate and well-controlled studies in pregnant women. May cause harm if administered during pregnancy. Effective contraception is recommended for men and women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F227181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10245667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Thiotepa Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $300.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F227147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count (monitor weekly during treatment and for at least 3 weeks after treatment); renal and liver function tests; uric acid, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ledertepa (BE, LU, NL);",
"     </li>",
"     <li>",
"      Oncotiotepa (BE, ES, LU);",
"     </li>",
"     <li>",
"      Tepadina (GB);",
"     </li>",
"     <li>",
"      Tespamin (JP, TW);",
"     </li>",
"     <li>",
"      Thio-Tepa (AR, CZ);",
"     </li>",
"     <li>",
"      Thiooplex (GR, IT);",
"     </li>",
"     <li>",
"      Thiotepa Lederle (AT, CH, DE, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent that reacts with DNA phosphate groups to produce cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; mechanism of action has not been explored as thoroughly as the other alkylating agents, it is presumed that the aziridine rings open and react as nitrogen mustard; reactivity is enhanced at a lower pH",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Intracavitary instillation: Unreliable (10% to 100%) through bladder mucosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; major metabolite (active): TEPA",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal (dose-dependent clearance): ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites and unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abrey LE, Childs BH, Paleologos N, et al, &ldquo;High-Dose chemotherapy With Stem Cell Rescue as Initial Therapy for anaplastic Oligodendroglioma: Long-Term Follow-Up,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2008, 89(2):187-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/18458821/pubmed\" id=\"18458821\" target=\"_blank\">",
"        18458821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badalament RA and Farah RN, &ldquo;Treatment of Superficial Bladder Cancer With Intravesicle Chemotherapy,&rdquo;",
"      <i>",
"       Semin Surg Oncol",
"      </i>",
"      , 1997, 13(5):335-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/9259089/pubmed\" id=\"9259089\" target=\"_blank\">",
"        9259089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeAngelis LM and Butros D, &ldquo;Leptomeningeal Metastasis,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 2005, 23(2):145-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/15813508/pubmed\" id=\"15813508\" target=\"_blank\">",
"        15813508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringer's Solution for Intrathecal Administration,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2009, 15(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/18772215 /pubmed\" id=\"18772215 \" target=\"_blank\">",
"        18772215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkel IJ, Gardner SL, Garvin JH Jr, et al, &ldquo;High-Dose Carboplatin, Thiotepa, and Etoposide With Autologous Stem Cell Rescue for Patients With Previously Irradiated Recurrent Medulloblastoma,&rdquo;",
"      <i>",
"       Neuro Oncol",
"      </i>",
"      , 2010, 12(3):297-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/20167818/pubmed\" id=\"20167818\" target=\"_blank\">",
"        20167818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilheeney SW, Khakoo Y, Souweidane M, et al, &ldquo;Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010, 54(4):591-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/19998470/pubmed\" id=\"19998470\" target=\"_blank\">",
"        19998470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodman H, Wolfe L, and Kretschmar C, &ldquo;Outcome of Patients With Recurrent Medulloblastoma or Central Nervous System Germinoma Treated With Low Dose Continuous Intravenous Etoposide Along With Dose-Intensive Chemotherapy Followed by Autologous Hematopoietic Stem Cell Rescue,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(1):33-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/19326417/pubmed\" id=\"19326417\" target=\"_blank\">",
"        19326417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman SA, Finkelstein DM, Ruckeschel JC, et al, &ldquo;Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(3):561-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/8445432/pubmed\" id=\"8445432\" target=\"_blank\">",
"        8445432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutin PH, Weiss HD, Wiernik PH, et al, &ldquo;Intrathecal N,N&prime;,N&prime;&prime;-triethylenethiophosphoramide [thio-TEPA (NSC-6396)] in the Treatment of Malignant Meningeal Disease: Phase I-II Study,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1976, 38(4):1471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/825215/pubmed\" id=\"825215\" target=\"_blank\">",
"        825215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heideman R, Cole D, Balis F, et al, &ldquo;Phase I and Pharmacokinetic Evaluation of Thiotepa in the Cerebrospinal Fluid and Plasma of Pediatric Patients: Evidence for Dose-Dependent Plasma Clearance of Thiotepa,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1989, 49(3):736-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/2491958/pubmed\" id=\"2491958\" target=\"_blank\">",
"        2491958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maanen MJ, Smeets CJ, and Beijnen JH, &ldquo;Chemistry, Pharmacology and Pharmacokinetics of N,N',N\", -Triethylenethiophosphoramide (ThioTEPA),\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2000, 26(4):257-68.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soussain C, Hoang-Xuan K, Taillandier L, et al, &ldquo;Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle Osseuse-Th&eacute;rapie Cellulaire,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15):2512-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35414/abstract-text/18413641/pubmed\" id=\"18413641\" target=\"_blank\">",
"        18413641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9992 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-0E38AEEEDF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35414=[""].join("\n");
var outline_f34_37_35414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227204\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10245670\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227172\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10245671\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10245672\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227149\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227134\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227152\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227210\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227150\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349164\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402289\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227202\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227155\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227138\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227199\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227143\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227166\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227145\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3881813\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227181\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10245667\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323960\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227147\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038841\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227137\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227154\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/12/35012?source=related_link\">",
"      Thiotepa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/42/27302?source=related_link\">",
"      Thiotepa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_37_35415="LIP with nodular inflammation";
var content_f34_37_35415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocytic interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathology of&nbsp;lung biopsy showing lymphocytic interstitial pneumonia&nbsp;with diffuse nodular inflammation of the pulmonary interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35415=[""].join("\n");
var outline_f34_37_35415=null;
var title_f34_37_35416="Treatment of hirsutism";
var content_f34_37_35416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hirsutism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35416/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/37/35416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirsutism, defined as excessive male-pattern hair growth, affects between 5 and 10 percent of women of reproductive age. In some cases, hirsutism is mild and requires only reassurance and cosmetic therapy, while in others, it causes significant psychological distress and requires more extensive intervention.",
"   </p>",
"   <p>",
"    The treatment of hirsutism will be reviewed here. The pathogenesis, causes, and evaluation of hirsutism are discussed separately. Direct methods of hair removal are reviewed briefly here and in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=see_link\">",
"     \"Removal of unwanted hair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When reviewing treatment options for women with hirsutism, a number of issues should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To what degree is the patient bothered by her hirsutism? We agree with the 2008 Endocrine Society guidelines that treatment decisions should be based upon the degree to which the excess hair bothers the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Does the patient have polycystic ovary syndrome (PCOS)? It is estimated that up to 70 to 80 percent of women with hirsutism have PCOS. These women have additional abnormalities that require attention, including oligoovulation, obesity, and an increased risk of type 2 diabetes. We often recommend weight loss as the initial step, a strategy that, if successful, results in improved insulin sensitivity, a decrease in serum androgens and, in some cases, a return of ovulatory cycles. Although an improvement in hirsutism would also be anticipated, this has not been well studied. The management of PCOS is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"       \"Treatment of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What are the patient's goals and expectations? Reasonable expectations should be fostered; women should be aware that drug therapy is unlikely to completely eliminate hair growth, but that hair may become less coarse, grow more slowly, and require less frequent use of cosmetic methods (shaving, plucking, waxing).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After this initial discussion, we review the available pharmacological options and methods of direct hair removal (photoepilation and electrolysis). Our treatment recommendations are consistent with the 2008 Endocrine Society guidelines, which are discussed in the remainder of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Endocrine Society has published evidence-based guidelines for the evaluation and treatment of hirsutism in premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ]. The guidelines note that experts often make treatment recommendations based upon the severity of the hirsutism, as measured by a modified Ferriman-Gallwey score, a method that grades hair growth on a scale of 0 to 4 in nine androgen-sensitive areas (",
"    <a class=\"graphic graphic_figure graphicRef66629 \" href=\"mobipreview.htm?35/12/36035\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Mild and severe hirsutism are considered to be scores of &ge;8 to 15 and &gt;15, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of premenopausal women with hirsutism\", section on 'Ferriman-Gallwey score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines present an alternative approach that is based upon the impact of the hirsutism on the patient's sense of well-being, rather than a Ferriman-Gallwey score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ]. We agree with this approach, based upon a number of arguments, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many clinicians are unfamiliar with calculating Ferriman-Gallwey scores.",
"     </li>",
"     <li>",
"      The Ferriman-Gallwey score, which is based upon Caucasian women, is unreliable in women of other ethnic backgrounds, as there is significant",
"      <span class=\"nowrap\">",
"       ethnic/racial",
"      </span>",
"      variability in expression of hair growth. As an example, Asian women with hyperandrogenemia are less likely than Caucasian women to develop hirsutism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although hirsutism is defined as a score &gt;8, most women with a score &gt;3 consider themselves to be hirsute [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, many women with low scores seek treatment because they are as distressed by their hair growth as women with high scores.",
"     </li>",
"     <li>",
"      Most women use cosmetic measures prior to their initial consultation, making it difficult to obtain an accurate score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines coined the term \"patient-important hirsutism\" to refer to hirsutism that causes sufficient distress (whether treated or untreated) for the patient to seek additional treatment. For women with \"patient-important hirsutism\" despite cosmetic measures, they suggest either pharmacological or direct hair removal methods. However, the majority of women with hirsutism are hyperandrogenemic and will experience hair regrowth if they are treated with direct hair removal methods alone. Therefore, for any woman with known hyperandrogenemia who choose hair removal methods, they suggest the addition of pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's assessment of her response to therapy is the most important outcome. At each follow-up visit, the patient should be asked whether she has noted any decreased need for cosmetic methods (shaving, plucking, waxing) to manage her hirsutism.",
"   </p>",
"   <p>",
"    In addition, we do try to obtain a Ferriman-Gallwey score at baseline and at each follow-up visit (",
"    <a class=\"graphic graphic_figure graphicRef66629 \" href=\"mobipreview.htm?35/12/36035\">",
"     figure 1",
"    </a>",
"    ). However, as noted, the score is unreliable in some ethnic groups (eg, Asian women), and in women who routinely use cosmetic hair removal methods.",
"   </p>",
"   <p>",
"    We do not suggest routine monitoring of serum androgens to assess the response to drug therapy. However, if there is progression of hirsutism during therapy, repeat biochemical evaluation is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After drug therapy is begun, a significant reduction in hair growth may not occur for up to six months, the approximate half-life of a hair follicle. After six months, if the patient feels that the response has been suboptimal, options to consider include a change in dose or drug, or addition of a second agent.",
"   </p>",
"   <p>",
"    Pharmacological therapy is usually continued during the reproductive years as the underlying condition typically persists during this window and hirsutism recurs when treatment is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pregnancy is desired, all pharmacological treatments for hirsutism must be discontinued. Antiandrogens, in particular, are contraindicated in women trying to conceive because of potential adverse effects on male sexual development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929892094\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929892102\">",
"    <span class=\"h2\">",
"     Cosmetic methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical methods of removing hair or making it less visible (shaving, plucking, waxing, bleaching) can be effective, and their use is reasonable either alone or as a supplement to drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=see_link\">",
"     \"Removal of unwanted hair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929892109\">",
"    <span class=\"h2\">",
"     Permanent hair reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct or mechanical methods of hair removal, including electrolysis and photoepilation (laser and intense pulsed light), are also referred to as \"permanent\" hair reduction techniques. However, women with underlying hyperandrogenemia are likely to experience hair regrowth because of the continued stimulation of hair follicles by endogenous androgens. This can be prevented by suppressing endogenous androgens with pharmacologic therapy, as described in the following section. Direct methods of hair removal are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=see_link\">",
"     \"Removal of unwanted hair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives are considered to be the first line drug for the management of hirsutism; an antiandrogen is added if the clinical response is suboptimal after six months of therapy. Insulin lowering agents are not considered to be an effective therapy for hirsutism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929891898\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the majority of women with hirsutism who choose pharmacological therapy, we suggest estrogen-progestin contraceptives as initial therapy. Efficacy data come primarily from oral contraceptive (OC) studies, but transdermal and vaginal estrogen-progestin contraceptive preparations are also considered to be effective. These preparations also provide additional non-hirsutism benefits such as contraception and cycle management. The mechanisms by which OCs reduce serum androgens and therefore hirsutism include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of luteinizing hormone (LH) secretion and therefore LH-dependent ovarian androgen production",
"     </li>",
"     <li>",
"      Increased hepatic synthesis of sex hormone-binding globulin (SHBG) by estrogen, resulting in decreased concentrations of serum free testosterone and other SHBG-bound androgens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhibition of adrenal androgen secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is estimated that 60 to 100 percent of hyperandrogenic women experience a significant reduction in hair growth with OC therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/10\">",
"     10",
"    </a>",
"    ]. However, clinical trial data on the impact of OCs on hirsutism are surprisingly limited. The best evidence comes from a pooled analysis of two trials in 34 women comparing OCs with either placebo or no therapy; OC therapy was associated with a greater reduction in Ferriman-Gallwey hirsutism scores (mean difference in score reduction 8.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with PCOS, estrogen-progestin contraceptives provide the additional benefit of preventing the development of endometrial hyperplasia. The treatment of PCOS and the use of oral contraceptives for hirsutism are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OC therapy is usually begun with a formulation that contains 30 to 35 mcg of ethinyl estradiol. The lower dose 20 mcg ethinyl estradiol formulations suppress serum androgens to a somewhat lesser degree, unless administered continuously. They are effective for acne, but have not been studied for hirsutism. We suggest switching to the 20 mcg formulations in women over age 40 years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on '20 to 25 mcg'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically choose an OC that contains a progestin with low androgenicity (or an antiandrogen such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    or drospirenone). In theory, OCs containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    , the most androgenic progestin, should be avoided because of concerns that it would worsen hirsutism. However, limited clinical trial data suggest that these preparations have similar benefit for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/13\">",
"     13",
"    </a>",
"    ]. Levonorgestrel may also have an adverse effect on metabolic markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/14\">",
"     14",
"    </a>",
"    ], but there are no data to suggest these are associated with adverse clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'OCs and insulin sensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiandrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antiandrogens are an effective therapy for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/15\">",
"     15",
"    </a>",
"    ], we suggest not using them as monotherapy, because of the potential adverse effects on a developing male fetus in utero. However, in women who cannot conceive or who are using a reliable contraceptive method, antiandrogens may be considered for monotherapy.",
"   </p>",
"   <p>",
"    In addition, we suggest adding an antiandrogen in women taking OCs who feel that their cosmetic response is suboptimal after six months.",
"   </p>",
"   <p>",
"    Available antiandrogens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      , an aldosterone and androgen receptor antagonist that is structurally similar to progestins. It competes with dihydrotestosterone (DHT) for binding to the androgen receptor, and inhibits enzymes involved in androgen biosynthesis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"       Cyproterone acetate",
"      </a>",
"      (CPA), a 17-hydroxyprogesterone derivative, competes with DHT for binding to the androgen receptor and reduces serum LH and ovarian androgen concentrations. It is used in a low dose (2 mg) as the progestin component of OCs, or as a higher dose (12.5 to 100 mg) as monotherapy or with estrogen. It is available in almost all countries but the United States.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      inhibits type 2 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone. Only a partial inhibitory effect occurs when used for excess hair growth, because the enhanced 5-alpha-reductase activity in hirsutism involves both the type 1 and type 2 enzymes.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       Dutasteride",
"      </a>",
"      , an inhibitor of both types 1 and 2 5-alpha-reductase, is available for the treatment of benign prostatic hyperplasia. No clinical trial data are available for dutasteride use in hirsute women.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"       Flutamide",
"      </a>",
"      is a nonsteroidal androgen receptor antagonist. It is used primarily in the management of prostate cancer, but has been used off-label for managing hirsutism.",
"     </li>",
"     <li>",
"      Drospirenone, a progestin used in some oral contraceptives, is a very weak antiandrogen. The dose used with ethinyl estradiol in oral contraceptives (3 mg) is equivalent to approximately 25 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"       1",
"      </a>",
"      ]. Drospirenone alone is not available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/16\">",
"     16",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/17\">",
"     17",
"    </a>",
"    ] trials have previously reported that both drugs are more effective than placebo for hirsutism.",
"   </p>",
"   <p>",
"    The best available evidence for the effect of antiandrogen therapy on hirsutism comes from a systematic review and meta-analysis of randomized, clinical trials that was performed in conjunction with the development of the 2008 Endocrine Society guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473061\">",
"    <span class=\"h4\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analysis of five trials of antiandrogen therapy in 170 patients (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    ) showed a significant reduction in Ferriman-Gallwey scores with antiandrogens compared with placebo (mean decrease 4.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/18\">",
"     18",
"    </a>",
"    ]. Although head-to-head comparisons of individual antiandrogens were not performed as part of this analysis, each of the three antiandrogens was more effective than placebo, and there did not appear to be important differences among the three drugs compared with placebo.",
"   </p>",
"   <p>",
"    Only one trial comparing an OC (containing low dose CPA) to an antiandrogen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ) was identified; no significant difference in hirsutism score was seen.",
"   </p>",
"   <p>",
"    In three trials comparing antiandrogen therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , the antiandrogen group had a significantly greater reduction in hirsutism scores (-3.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473069\">",
"    <span class=\"h4\">",
"     Combination OC-antiandrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an analysis of four trials, the addition of an antiandrogen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ) to an OC was slightly more effective than an OC alone (mean difference in hirsutism score -1.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Choice of antiandrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few comparative studies of different antiandrogens in women with hirsutism. Since they all appear to be effective for hirsutism, the choice of drug depends upon its availability, cost, side effects, and potential toxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      , as clinical trials have shown consistent benefit, and it is considered to be safe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1,19,20\">",
"       1,19,20",
"      </a>",
"      ]. We start with 50 mg twice daily, and increase to 100 mg twice daily as needed. The side effects of spironolactone include hyperkalemia (which is rarely a problem in women with normal renal function and aldosterone secretion), gastrointestinal discomfort, and irregular menstrual bleeding that is often managed by switching to or adding an OC.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is used by some clinicians, but there are particular concerns about its inadvertent use in early pregnancy, given the essential role of dihydrotestosterone in the development of male external genitalia. The package insert currently warns against women using it, and warns that pregnant women should not touch any pill that has been crushed or broken because of the potential risk to the fetus. In addition, many clinicians have limited experience with its use in women, and it is considerably more expensive than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      . We suggest not using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      , given the absence of clinical trial data.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"       Flutamide",
"      </a>",
"      (250 to 750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is equally or even more effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/18,21-24\">",
"       18,21-24",
"      </a>",
"      ]. However, we suggest against its use for hirsutism since it has been associated with hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/25,26\">",
"       25,26",
"      </a>",
"      ], even at relatively low doses of 125 to 250 mg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/27\">",
"       27",
"      </a>",
"      ]. While a lower dose (62.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      has not been associated with hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/28-31\">",
"       28-31",
"      </a>",
"      ], it has not been shown to be effective for hirsutism.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"       Cyproterone acetate",
"      </a>",
"      , while effective for hirsutism, is not available in the United States, and drug regulatory agencies in Europe have recommended limiting its use to \"second-line\" therapy because of a perceived increase in risk of hepatotoxicity compared with other available progestins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin-lowering drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin lowering drugs, which have been used for a number of indications, do not appear to be effective for hirsutism.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    are used primarily for blood glucose control in patients with type 2 diabetes, but have also been used for a number of indications in women with polycystic ovary syndrome (PCOS), including restoration of ovulatory cycles. In addition to lowering serum insulin concentrations, both agents reduce serum androgen concentrations, and have therefore been used as a potential treatment for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1,34\">",
"     1,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available evidence for their possible efficacy for hirsutism comes from a second systematic review and meta-analysis performed in conjunction with the development of the 2008 Endocrine Society guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/35\">",
"     35",
"    </a>",
"    ]. Meta-analysis of eight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    trials found no significant reduction in Ferriman-Gallwey scores with metformin when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/35\">",
"     35",
"    </a>",
"    ]. Additional details of this meta-analysis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link&amp;anchor=H13#H13\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Hirsutism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2008 Endocrine Society guidelines and suggest against their routine use for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ], as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has minimal or no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , while modestly effective for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/35\">",
"     35",
"    </a>",
"    ], is associated with weight gain and possible adverse cardiovascular effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link&amp;anchor=H13#H13\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Hirsutism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Insulin-lowering agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     GnRH agonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with hirsutism, administration of a gonadotropin-releasing hormone (GnRH) agonist inhibits gonadotropin and ovarian androgen secretion, resulting in decreased hair growth, but also estrogen deficiency. The combination of a GnRH agonist with either low-dose estrogen and progesterone or an oral contraceptive eliminates the adverse effects of estrogen deficiency without diminishing the benefits of the GnRH agonist. This approach is a potential option in women who develop blood pressure elevations when using oral contraceptives. These regimens are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32005?source=see_link\">",
"     \"Use of GnRH agonists in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2008 Endocrine Society guidelines, and suggest against the routine use of GnRH agonists for hirsutism, because it involves a complicated and expensive regimen, and there are other effective therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous glucocorticoids, which suppress hypothalamic corticotropin-releasing hormone (CRH) production and, therefore, pituitary corticotropin (ACTH) and adrenal androgen production, are used long-term to manage hirsutism and maintain ovulatory cycles in women with classic 21-hydroxylase (CYP21A2) deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7433?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    They have also been used to treat hirsutism in women with the nonclassic form of CYP21A2 deficiency (NCCAH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and unselected women with hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], with only minimal benefit. In two trials of glucocorticoid therapy in women with NCCAH (one randomized, one non-randomized), glucocorticoids were more effective than OCs or antiandrogens for suppressing serum adrenal androgen concentrations (dehydroepiandrosterone and dehydroepiandrosterone sulfate [DHEA and DHEAS]), but less effective for decreasing hirsutism scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=see_link\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given their relative lack of benefit for hirsutism and their potential side effects, we agree with the 2008 Endocrine Society guidelines and suggest against glucocorticoid therapy for the routine treatment of hirsutism. An exception is in women with nonclassic congenital adrenal hyperplasia who do not respond to or cannot tolerate oral contraceptive and antiandrogen therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"     1",
"    </a>",
"    ]. Glucocorticoids are also indicated for ovulation induction in women with NCCAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=see_link\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Multidrug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;European investigators have studied the following combinations for the treatment of hirsutism:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An estrogen-progestin contraceptive plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/31,42\">",
"       31,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An estrogen-progestin contraceptive plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      in adolescents and women with hirsutism and oligomenorrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combinations in these trials were effective in the treatment of hirsutism. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    reduced the accumulation of visceral fat, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    improved insulin sensitivity.",
"   </p>",
"   <p>",
"    In the absence of additional clinical trial data for these regimens, we suggest against their routine use. In addition, as noted above, we do not recommend treating hirsutism with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    because of potential hepatotoxicity and because there are other effective and safer antiandrogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaniqa (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    hydrochloride cream 13.9 percent) is a topical drug that is available for the treatment of unwanted facial hair in women. It is an inhibitor of hair growth, not a depilatory, and must be used indefinitely to prevent regrowth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In two clinical trials of combined eflornithine and laser therapy, a more rapid response was observed when compared with laser treatments alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. We suggest using eflornithine cream in women who desire a more rapid response to laser therapy.",
"   </p>",
"   <p>",
"    Limited data suggest that topical canrenone (the active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    provide little or no benefit for hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35416/abstract/4,48\">",
"     4,48",
"    </a>",
"    ]. Thus, we suggest against their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTMENOPAUSAL WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In postmenopausal women with new hirsutism that is severe or rapidly progressive, the possibility of an androgen-secreting tumor must be excluded before initiating treatment. If there is no evidence of a tumor, treatment options include antiandrogens, or hormone therapy with a combination of estrogen and an antiandrogen such as drospirenone. In menopausal women with ovarian stromal hyperthecosis and severe hirsutism, bilateral oophorectomy may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/56/9090?source=see_link\">",
"       \"Patient information: Hirsutism (excess hair growth in women) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/24/13698?source=see_link\">",
"       \"Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Our approach to the treatment of hirsutism is consistent with the 2008 Endocrine Society guidelines. For women with \"patient-important\" hirsutism in spite of cosmetic measures, available options include pharmacological therapy and direct hair removal methods. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473123\">",
"    <span class=\"h2\">",
"     Direct hair removal methods",
"    </span>",
"   </p>",
"   <p>",
"    For women with hyperandrogenism undergoing direct hair removal methods, we suggest that pharmacological therapy be added or continued to minimize hair regrowth (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H929892109\">",
"     'Permanent hair reduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacological",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For hirsute women with known hyperandrogenism such as polycystic ovary syndrome (PCOS), we suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For any pharmacological therapy, we suggest a minimum of six months before making changes in dose, type of medication, or adding a medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Monotherapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of women with hirsutism who choose pharmacological therapy, we suggest oral contraceptives as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacologic management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although we do not suggest one particular OC over another, it is reasonable to avoid preparations with the most androgenic progestin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      , which has less desirable metabolic effects. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacologic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of their potential teratogenic effect, antiandrogen monotherapy should not be used in women of reproductive age unless reliable contraception is used. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antiandrogen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not routinely using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      for hirsutism (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of antiandrogen'",
"      </a>",
"      above.) Although it may be more effective than other antiandrogens, flutamide has been associated with potential hepatotoxicity and is considerably more expensive than other antiandrogens. Low dose flutamide (62.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      does not appear to be associated with hepatotoxicity, but it has not been studied as monotherapy for hirsutism.",
"     </li>",
"     <li>",
"      We suggest not using insulin-lowering drugs for hirsutism (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insulin-lowering drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with a suboptimal cosmetic result after six months of oral contraceptive monotherapy, we suggest adding an antiandrogen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antiandrogen therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/1\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/2\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/3\">",
"      Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/4\">",
"      Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/5\">",
"      DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 2006; 91:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/6\">",
"      Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol (Oxf) 2000; 52:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/7\">",
"      Koulouri O, Conway GS. Management of hirsutism. BMJ 2009; 338:b847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/8\">",
"      Granger LR, Roy S, Mishell DR Jr. Changes in unbound sex steroids and sex hormone binding globulin--binding capacity during oral and vaginal progestogen administration. Am J Obstet Gynecol 1982; 144:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/9\">",
"      Madden JD, Milewich L, Parker CR Jr, et al. The effect of oral contraceptive treatment on the serum concentration of dehydroisoandrosterone sulfate. Am J Obstet Gynecol 1978; 132:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/10\">",
"      Burkman RT Jr. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995; 98:130S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/11\">",
"      Saeed, R, Akram, J, Changezi, HE, Saeed, M. Specialist 1993; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/12\">",
"      Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991; 55:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/13\">",
"      Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003; 67:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/14\">",
"      Knopp RH, Broyles FE, Cheung M, et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/15\">",
"      Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000; 52:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/16\">",
"      Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003; :CD001125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/17\">",
"      Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009; :CD000194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/18\">",
"      Swiglo BA, Cosma M, Flynn DN, et al. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/19\">",
"      Lobo RA, Shoupe D, Serafini P, et al. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/20\">",
"      Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/21\">",
"      Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/22\">",
"      Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/23\">",
"      Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/24\">",
"      M&uuml;derris II, Bayram F, G&uuml;ven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000; 73:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/25\">",
"      Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/26\">",
"      Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/27\">",
"      Brahm J, Brahm M, Segovia R, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/28\">",
"      Ib&aacute;&ntilde;ez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/29\">",
"      Ib&aacute;&ntilde;ez L, De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 2003; 88:4720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/30\">",
"      Ib&aacute;&ntilde;ez L, De Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 2004; 19:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/31\">",
"      Ib&aacute;&ntilde;ez L, Ong K, Ferrer A, et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/32\">",
"      Anonymous. Germany's cyproterone warning. Lancet 1995; 345:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/33\">",
"      Heinemann LA, Will-Shahab L, van Kesteren P, et al. Safety of cyproterone acetate: report of active surveillance. Pharmacoepidemiol Drug Saf 1997; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/34\">",
"      Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/35\">",
"      Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/36\">",
"      Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; :CD005552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/37\">",
"      Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990; 70:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/38\">",
"      Frank-Raue K, Junga G, Raue F, et al. [Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate]. Klin Wochenschr 1990; 68:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/39\">",
"      Carmina E, Lobo RA. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstet Gynecol 1991; 78:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/40\">",
"      Carmina E, Lobo RA. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. Fertil Steril 1998; 69:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/41\">",
"      Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990; 70:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/42\">",
"      Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91:3970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/43\">",
"      Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005; 118:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/44\">",
"      \"The Pink Sheet\". August 7, 2000; 62:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/45\">",
"      Wolf JE Jr, Shander D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol 2007; 46:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/46\">",
"      Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006; 32:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/47\">",
"      Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007; 57:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35416/abstract/48\">",
"      Gomez F, Ramelet AA, R&uuml;edi B, M&uuml;hlemann M. Lack of effect of a spironolactone-containing cream on hair growth in hirsute women. Dermatologica 1987; 174:102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7444 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35416=[""].join("\n");
var outline_f34_37_35416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H929892094\">",
"      NONPHARMACOLOGIC METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929892102\">",
"      Cosmetic methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929892109\">",
"      Permanent hair reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929891898\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiandrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H473061\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H473069\">",
"      Combination OC-antiandrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Choice of antiandrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin-lowering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - GnRH agonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Multidrug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTMENOPAUSAL WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473123\">",
"      Direct hair removal methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacological",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7444|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/12/36035\" title=\"figure 1\">",
"      Grading of hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=related_link\">",
"      Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/24/13698?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/56/9090?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=related_link\">",
"      Removal of unwanted hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7433?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32005?source=related_link\">",
"      Use of GnRH agonists in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27928?source=related_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_37_35417="Atorvastatin: Drug information";
var content_f34_37_35417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atorvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/47/6901?source=see_link\">",
"    see \"Atorvastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=see_link\">",
"    see \"Atorvastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13842381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lipitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atorvastatin&reg;;",
"     </li>",
"     <li>",
"      Ava-Atorvastatin;",
"     </li>",
"     <li>",
"      CO Atorvastatin;",
"     </li>",
"     <li>",
"      Dom-Atorvastatin;",
"     </li>",
"     <li>",
"      GD-Atorvastatin;",
"     </li>",
"     <li>",
"      Lipitor&reg;;",
"     </li>",
"     <li>",
"      Mylan-Atorvastatin;",
"     </li>",
"     <li>",
"      Novo-Atorvastatin;",
"     </li>",
"     <li>",
"      PMS-Atorvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Atorvastatin;",
"     </li>",
"     <li>",
"      ratio-Atorvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Atorvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Primary prevention:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol concentrations, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypercholesterolemia (heterozygous familial and nonfamilial) and mixed hyperlipidemia (Fredrickson types IIa and IIb):",
"     </b>",
"     Oral: Initial: 10-20 mg once daily; patients requiring &gt;45% reduction in LDL-C may be started at 40 mg once daily; range: 10-80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     Oral: 10-80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Secondary prevention:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Clinically-evident coronary heart disease:",
"     </b>",
"     Oral: Initial: 80 mg once daily; adjust based on patient tolerability and recommended goal LDL-C (LaRosa, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intensive lipid-lowering after an ACS event regardless of baseline LDL (unlabeled use):",
"     </b>",
"     Oral: Initial: 80 mg once daily; adjust based on patient tolerability and recommended goal LDL-C (Cannon, 2004; Pederson, 2005; Schwartz, 2001).",
"     <b>",
"      Note:",
"     </b>",
"     Currently, the ACC/AHA guidelines for UA/NSTEMI do not specify which statin to use (Anderson, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Noncardioembolic stroke/TIA (unlabeled use):",
"     </b>",
"     Oral: Initial: 80 mg once daily; adjust based on patient tolerability and recommended goal LDL-C (Adams, 2008; Amarenco, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for atorvastatin with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Boceprevir, nelfinavir:",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 40 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir, or saquinavir):",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 20 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lomitapide:",
"     </i>",
"     Consider atorvastatin dose reduction (per lomitapide manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=see_link\">",
"      see \"Atorvastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol concentrations, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      HeFH:",
"     </b>",
"     Children 10-17 years (females &gt;1 year postmenarche): Oral: 10 mg once daily (maximum: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for atorvastatin with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Boceprevir, nelfinavir:",
"     </i>",
"     Lowest effective atorvastatin dose (not to exceed 40 mg/day) should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir, lopinavir, or saquinavir):",
"     </i>",
"     Lowest effective atorvastatin dose (not to exceed 20 mg/day) should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lomitapide:",
"     </i>",
"     Consider atorvastatin dose reduction (per lomitapide manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipitor&reg;: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food if desired; may take without regard to time of day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of dyslipidemias or primary prevention of cardiovascular disease (atherosclerotic) as detailed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Primary prevention of cardiovascular disease (high-risk for CVD): To reduce the risk of MI or stroke in patients without evidence of heart disease who have multiple CVD risk factors or type 2 diabetes. Treatment reduces the risk for angina or revascularization procedures in patients with multiple risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Secondary prevention of cardiovascular disease: To reduce the risk of nonfatal MI, nonfatal stroke, revascularization procedures, hospitalization for heart failure, and angina in patients with evidence of coronary heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of dyslipidemias: To reduce elevations in total cholesterol (C), LDL-C, apolipoprotein B, and triglycerides in patients with elevations of one or more components, and/or to increase low HDL-C as present in Fredrickson type IIa, IIb, III, and IV hyperlipidemias, heterozygous familial and nonfamilial hypercholesterolemia, and homozygous familial hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of heterozygous familial hypercholesterolemia (HeFH) in adolescent patients (10-17 years of age, females &gt;1 year postmenarche) having LDL-C &ge;190 mg/dL or LDL-C &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD) or with two or more CVD risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10512344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Secondary prevention in patients who have experienced a noncardioembolic stroke/TIA or following an ACS event regardless of baseline LDL-C using intensive lipid-lowering therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AtorvaSTATin may be confused with atoMOXetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lipitor&reg; may be confused with labetalol, Levatol&reg;, lisinopril, Loniten&reg;, Lopid&reg;, Mevacor&reg;, Zocor&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 7%), dyspepsia (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 3% with 80 mg/day dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Limb pain (3% to 9%), myalgia (3% to 8%), muscle spasms (2% to 5%), musculoskeletal pain (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Alkaline phosphatase increased, alopecia, amnesia (reversible), anaphylaxis, anemia, angioneurotic edema, anorexia, biliary pain, blood glucose increased, blurred vision, bullous rash, bullous rash, bursitis, cholestasis, cholestatic jaundice, cognitive impairment (reversible), colitis, confusion (reversible), CPK increased, depression, diabetes mellitus (new onset), dizziness, duodenal ulcer, dysphagia, ecchymosis, emotional lability, epistaxis, eructation, erythema multiforme, esophagitis, fatigue, flatulence, gastritis, gastroenteritis, gingival hemorrhage, glossitis, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, hematuria, hepatic failure, hepatitis, hyper-/hypoglycemia, incoordination, jaundice, joint swelling, leg cramps, malaise, melena, memory disturbance (reversible), memory impairment (reversible), metrorrhagia, migraine, muscle fatigue, myasthenia, myopathy, myositis, neck pain, neck rigidity, nephritis, nightmare, pancreatitis, paresthesia, parosmia, peripheral neuropathy, petechiae, photosensitivity, pruritus, rectal hemorrhage, rhabdomyolysis, Stevens-Johnson syndrome, stomatitis, syncope, taste loss, taste perversion, tendinous contracture, tendon rupture, tenesmus, thrombocytopenia, tinnitus, torticollis, toxic epidermal necrolysis, urticaria, vaginal hemorrhage, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with atorvastatin therapy): Cataracts, cirrhosis, dermatomyositis, eosinophilia, erectile dysfunction, extraocular muscle movement impaired, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, immune-mediated necrotizing myopathy (IMNM), interstitial lung disease, ophthalmoplegia, peripheral nerve palsy, polymyalgia rheumatica, positive ANA, renal failure (secondary to rhabdomyolysis), systemic lupus erythematosus-like syndrome, thyroid dysfunction, tremor, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atorvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Telaprevir Canadian product monograph contraindicates use with atorvastatin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart atorvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of CYP3A4 inhibitors (eg, clarithromycin, protease inhibitors), fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day) (see Drug Interactions). If concurrent use of clarithromycin or combination protease inhibitors (eg, lopinavir/ritonavir or ritonavir/saquinavir) is warranted consider dose adjustment of atorvastatin. Ensure patient is on the lowest effective atorvastatin dose in all circumstances. Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhagic stroke: Patients with a history of hemorrhagic stroke may be at increased risk for another hemorrhagic stroke with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen potential for CYP-mediated interactions. Do not use with cyclosporine, gemfibrozil, tipranavir plus ritonavir, or telaprevir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Secondary causes of hyperlipidemia should be ruled out prior to therapy. Atorvastatin has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: AtorvaSTATin may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of AtorvaSTATin. Management: Limit the atorvastatin maximum adult dose to 40 mg daily in patients receiving boceprevir.  Monitor clinical response to ensure that the lowest necessary atorvastatin dose is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest starting dose and titrate up slowly as needed while monitoring closely for evidence of atorvastatin adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: AtorvaSTATin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: AtorvaSTATin may increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with diltiazem.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): AtorvaSTATin may enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin.  Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: AtorvaSTATin may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of AtorvaSTATin. Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of AtorvaSTATin. Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F137658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may enhance the potential of adverse hepatic effects. Management: Avoid excessive ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Atorvastatin serum concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities of grapefruit juice (&gt;1 quart/day). Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease atorvastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1757842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take with food if desired; may take without regard to time of day. Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 3-6 months and the diet should be continued during drug therapy. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice. Atorvastatin serum concentration may be increased when taken with grapefruit juice; avoid concurrent intake of large quantities (&gt;1 quart/day).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atorvastatin Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $346.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $494.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $494.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $494.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lipitor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $540.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $770.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $770.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $660.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow-up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed within 2-4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Stin (KP);",
"     </li>",
"     <li>",
"      Actalipid (ID);",
"     </li>",
"     <li>",
"      Ale (CL);",
"     </li>",
"     <li>",
"      Anxolipo (TW);",
"     </li>",
"     <li>",
"      Atacor (HK);",
"     </li>",
"     <li>",
"      Atarva (AR);",
"     </li>",
"     <li>",
"      Atofar (ID);",
"     </li>",
"     <li>",
"      Atolow (KP);",
"     </li>",
"     <li>",
"      Atopitar (PH);",
"     </li>",
"     <li>",
"      Ator (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Atorcal (TW);",
"     </li>",
"     <li>",
"      Atorin (TW);",
"     </li>",
"     <li>",
"      Atoris (BE, RU);",
"     </li>",
"     <li>",
"      Atorlip (CO, HK, PE);",
"     </li>",
"     <li>",
"      Atorsan (ID, TH);",
"     </li>",
"     <li>",
"      Atorva (KP);",
"     </li>",
"     <li>",
"      Atorwin (PH);",
"     </li>",
"     <li>",
"      Atoty (TW);",
"     </li>",
"     <li>",
"      Atroact-10 (PH);",
"     </li>",
"     <li>",
"      Avamax (PH);",
"     </li>",
"     <li>",
"      Axo (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bestatin (PH);",
"     </li>",
"     <li>",
"      Cardyl (ES);",
"     </li>",
"     <li>",
"      Carvastin (PH);",
"     </li>",
"     <li>",
"      Citalor (BR);",
"     </li>",
"     <li>",
"      Enturion (SG);",
"     </li>",
"     <li>",
"      Hipolixan (CN);",
"     </li>",
"     <li>",
"      Lipiduce (HK);",
"     </li>",
"     <li>",
"      Lipigo (PH);",
"     </li>",
"     <li>",
"      Lipilou (KP);",
"     </li>",
"     <li>",
"      Lipinon (KP);",
"     </li>",
"     <li>",
"      Lipistad (HK);",
"     </li>",
"     <li>",
"      Lipiterol (KP);",
"     </li>",
"     <li>",
"      Lipitor (AE, AR, AU, BD, BE, BF, BH, BJ, BO, BR, CI, CL, CN, CO, CR, CY, DO, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PR, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lipivent (PH);",
"     </li>",
"     <li>",
"      Lipiwon (KP);",
"     </li>",
"     <li>",
"      Lipoactin (KP);",
"     </li>",
"     <li>",
"      Lipodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lipomax (PY);",
"     </li>",
"     <li>",
"      Lipomet (KP);",
"     </li>",
"     <li>",
"      Liponorm (EC);",
"     </li>",
"     <li>",
"      Litorva (IL);",
"     </li>",
"     <li>",
"      Lowlipen (CO);",
"     </li>",
"     <li>",
"      Newvast (KP);",
"     </li>",
"     <li>",
"      Rotaqor (MY);",
"     </li>",
"     <li>",
"      Sortis (AT, BG, CH, CZ, DE, PL, SE);",
"     </li>",
"     <li>",
"      Speetin (KP);",
"     </li>",
"     <li>",
"      Stator (ID);",
"     </li>",
"     <li>",
"      Storvas (IN, MY);",
"     </li>",
"     <li>",
"      Tahor (FR, MU);",
"     </li>",
"     <li>",
"      Torvast (IT);",
"     </li>",
"     <li>",
"      Tovast (KP);",
"     </li>",
"     <li>",
"      Truvast (PH);",
"     </li>",
"     <li>",
"      Truvaz (ID);",
"     </li>",
"     <li>",
"      Tulip (TW);",
"     </li>",
"     <li>",
"      Vaztor (PH);",
"     </li>",
"     <li>",
"      You Jia (CL);",
"     </li>",
"     <li>",
"      Zarator (AR, CN, DK, ES, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Initial changes: 3-5 days; Maximal reduction in plasma cholesterol and triglycerides: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~381 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &ge;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms active ortho- and parahydroxylated derivates and an inactive beta-oxidation product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~14% (parent drug); ~30% (parent drug and equipotent metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 14 hours; Equipotent metabolites: 20-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Bile; urine (&lt;2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams JA, Albers G, Alberts JS, et al, &ldquo;Update to the AHA/ASA Recommendations for the Prevention of Stroke on Patients With Stroke and Transient Ischemic Attack,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2008, 39(5):1647-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/18322260/pubmed\" id=\"18322260\" target=\"_blank\">",
"        18322260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amarenco P, Bogousslavsky J, Callahan A 3rd, et al, &ldquo;High-Dose Atorvastatin After Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(6):549-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/16899775/pubmed\" id=\"16899775\" target=\"_blank\">",
"        16899775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):671-719.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15358045/pubmed\" id=\"15358045\" target=\"_blank\">",
"        15358045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briguori C, Visconti G, Focaccio A, et al, &ldquo;Novel Approaches for Preventing or Limiting Events (Naples) II trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2157-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/19664895/pubmed\" id=\"19664895\" target=\"_blank\">",
"        19664895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon CP, Braunwald E, McCabe CH, et al, &ldquo;Intensive Versus Moderate Lipid Lowering With Statins After Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(15):1495-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15007110/pubmed\" id=\"15007110\" target=\"_blank\">",
"        15007110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson MH and Robinson JG, &ldquo;Safety of Aggressive Lipid Management,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 49(17):1753-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/17466224/pubmed\" id=\"17466224\" target=\"_blank\">",
"        17466224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al, &ldquo;Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients with Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 292(11):1307-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15337732/pubmed\" id=\"15337732\" target=\"_blank\">",
"        15337732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Di Sciascio G, Patti G, Pasceri V, et al, &ldquo;Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(6):558-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/19643320/pubmed\" id=\"19643320\" target=\"_blank\">",
"        19643320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15358046/pubmed\" id=\"15358046\" target=\"_blank\">",
"        15358046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren MJ, Smith DG, Hunninghake DB, et al, &ldquo;The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. A Comparison of Atorvastatin, Simvastatin, Lovastatin, and Fluvastatin,&rdquo;",
"      <i>",
"       Pharmacoeconomics",
"      </i>",
"      , 1998, 14(1):59-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/10182195/pubmed\" id=\"10182195\" target=\"_blank\">",
"        10182195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasceri V, Patti G, Nusca A, et al, &ldquo;Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(6):674-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/15277322/pubmed\" id=\"15277322\" target=\"_blank\">",
"        15277322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patti G, Pasceri V, Colonna G, et al, &ldquo;Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 49(12):1272-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/17394957/pubmed\" id=\"17394957\" target=\"_blank\">",
"        17394957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pederson TR, Faergerman O, Kastelein JJ, et al, &ldquo;High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 294(19):2437-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/16287954/pubmed\" id=\"16287954\" target=\"_blank\">",
"        16287954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Waters D, Brown WV, et al, &ldquo;Aggressive Lipid-Lowering Therapy Compared With Angioplasty in Stable Coronary Artery Disease. Atorvastatin Versus Revascularization Treatment Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(2):70-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/10395630/pubmed\" id=\"10395630\" target=\"_blank\">",
"        10395630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz GG, Olsson AG, Ezekowitz MD, et al, &ldquo;Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(13):1711-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/11277825/pubmed\" id=\"11277825\" target=\"_blank\">",
"        11277825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waters DD, LaRosa JC, Barter P, et al, &ldquo;Effects Of High-Dose Atorvastatin On Cerebrovascular Events In Patients With Stable Coronary Disease In The TNT (Treating To New Targets) Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(9):1793-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/37/35417/abstract-text/17084252/pubmed\" id=\"17084252\" target=\"_blank\">",
"        17084252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8949 Version 56.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35417=[""].join("\n");
var outline_f34_37_35417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842381\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137661\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137662\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137699\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137666\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137686\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137667\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137668\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137669\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137639\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137625\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137643\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137642\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512344\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137707\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137697\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137646\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137629\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137693\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137634\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137658\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137635\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1757842\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137673\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137649\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137648\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137637\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137650\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137628\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137645\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/47/6901?source=related_link\">",
"      Atorvastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=related_link\">",
"      Atorvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_37_35418="Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction";
var content_f34_37_35418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Venu Menon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Judith S Hochman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/37/35418/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/37/35418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock (CS) is a clinical condition of inadequate tissue (end-organ) perfusion due to cardiac dysfunction. The definition includes the following hemodynamic parameters: persistent hypotension (systolic blood pressure &lt;80 to 90 mmHg or mean arterial pressure 30 mmHg lower than baseline) with severe reduction in the cardiac index (&lt;1.8",
"    <span class=\"nowrap\">",
"     L/",
"    </span>",
"    min per m",
"    <sup>",
"     2",
"    </sup>",
"    without support or &lt;2.0 to 2.2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m",
"    <sup>",
"     2",
"    </sup>",
"    with support) and adequate or elevated filling pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/1\">",
"     1",
"    </a>",
"    ]. Short-term prognosis is directly related to the severity of the hemodynamic disorder.",
"   </p>",
"   <p>",
"    The most common etiology of CS is an acute myocardial infarction (usually ST elevation myocardial infarction) with left ventricular failure, but it can also be caused by mechanical complications, such as acute mitral regurgitation or rupture of either the ventricular septal or free walls. However, any cause of acute, severe left or right ventricular dysfunction may lead to CS.",
"   </p>",
"   <p>",
"    The prognosis and therapy of CS complicating acute myocardial infarction (MI) will be reviewed here. The larger discussion of the causes of CS, other presentations that mimic CS secondary to MI, as well as the clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Temporal trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of CS appears to be falling since the mid 1970s. In a report from one United States metropolitan area (Worcester, Massachusetts) the incidence of CS was around 7 percent between 1975 and 1990 and has decreased to between 5.5 to 6.0 percent since then [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The historic mortality rate for CS complicating an acute MI was 80 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/3\">",
"     3",
"    </a>",
"    ]. However, lower values for in-hospital mortality have been noted in more studies, ranging from 48 to 74 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Studies have suggested short-term mortality rates between 42 and 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two reports from the National Registry of Myocardial Infarction showed evidence of continued improvement in mortality from CS between 1994 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/5\">",
"     5",
"    </a>",
"    ]. Similar findings were noted in an analysis of over 23,000 acute coronary syndrome patients in a Swiss registry (1997 to 2006) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These improvements in the incidence of shock and the associated mortality in part reflect increased use of coronary reperfusion strategies, particularly primary percutaneous coronary intervention, which, by restoring patency to the infarct-related artery, can limit infarct size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/5-7,12\">",
"     5-7,12",
"    </a>",
"    ]. The time trend towards better outcomes may also be attributable to improvements in the medical care of these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predictors of mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have attempted to identify risk factors for mortality in CS. An analysis from the GUSTO-I database identified the following predictors of 30-day survival for patients with CS complicating an STEMI who receive initial fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing age (odds ratio 1.49 for each 10 year increase)",
"     </li>",
"     <li>",
"      Prior MI",
"     </li>",
"     <li>",
"      Physical findings at the time of diagnosis (the presence of altered sensorium and cold, clammy skin)",
"     </li>",
"     <li>",
"      Oliguria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemodynamic parameters (including basic vital signs and measurements obtained from pulmonary artery catheterization) also correlate with mortality in patients with CS. These parameters include mean arterial pressure (MAP), systolic and diastolic blood pressure, cardiac output (CO) and cardiac index, with cardiac power index (MAP x",
"    <span class=\"nowrap\">",
"     CO/451",
"    </span>",
"    x body surface area in m",
"    <sup>",
"     2",
"    </sup>",
"    ) being the strongest hemodynamic predictor on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     STEMI versus NSTEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate in patients in CS in GUSTO-IIb was similar in those with STEMI or non-ST elevation acute coronary syndrome (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/8\">",
"     8",
"    </a>",
"    ]. Although CS was significantly less common with non-ST elevation infarcts (2.5 versus 4.2 percent, odds ratio 0.58), patients with non-ST elevation acute coronary syndromes were older and more likely to have three vessel disease and diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Coronary anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CS complicating an acute MI have severe and extensive coronary disease. In the SHOCK trial registry, for example, 16 percent of those who underwent angiography had significant left main disease and 53 percent had three vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"     15",
"    </a>",
"    ]. Mortality varied significantly with the location of the culprit lesion and was noted to be higher in patients with a left main or saphenous vein graft lesion than in those with circumflex, left anterior descending, or right coronary artery lesions (79 and 70 percent versus 37 to 42 percent). Right coronary culprit lesions were associated with the best prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Echocardiographic predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a substudy from the SHOCK trial, 169 patients had echocardiograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/17\">",
"     17",
"    </a>",
"    ]. The only independent echocardiographic predictors of outcome were left ventricular ejection fraction (LVEF) and severity of mitral regurgitation (MR). For those with an LVEF &lt;28 percent, survival at one year was 24 percent (versus 56 percent for those with a higher LVEF). For those with moderate or severe MR, survival at one year was 31 percent (versus 58 percent for those with mild or no MR). However, there was benefit of early revascularization at all levels of LVEF and MR grade. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'SHOCK trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Symptom onset to reperfusion time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time from symptom onset to reperfusion is an important determinant of mortality in patients with STEMI who undergo primary PCI. An analysis of 80 such patients who were in CS showed that in-hospital mortality was only 6.2 percent in patients reperfused within two hours of symptom onset; this was more likely to occur in patients diagnosed with MI in the prehospital arena [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     After successful reperfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early successful reperfusion therapy, particularly with percutaneous coronary intervention, improves outcomes compared with conservative (medical) therapy. The magnitude of this benefit is discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Reperfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe systemic hypoperfusion leads to hypoxemia and lactic acidosis, which can cause further myocardial depression both directly and by decreasing the responsiveness to vasopressors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    . Thus, if possible, correction of these metabolic disturbances is important (",
"    <a class=\"graphic graphic_table graphicRef82406 \" href=\"mobipreview.htm?4/44/4812\">",
"     table 1",
"    </a>",
"    ). In addition, shock in the setting of MI may be caused by factors not directly related to the MI. These include hypovolemia, use of blood pressure lowering drugs, rate slowing drugs, and other types of cardiovascular disease; they are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Contributing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion is generally in accord with recommendations made in the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of patients with STEMI, which were not changed in the 2007 Focused Update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Similar principles apply to patients with NSTEMI (",
"    <a class=\"graphic graphic_table graphicRef54567 \" href=\"mobipreview.htm?16/5/16476\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and vasopressors are frequently given in CS, while certain other medications should be avoided or used in reduced dose. Medications that have hepatic or renal clearance should be used in reduced doses because of hypoperfusion of these organs. One important example is use of a lower dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , which is rarely given to treat ventricular arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oral antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reduce mortality from acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that all patients with CS complicating an acute MI receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    even though its efficacy has not been specifically studied in this setting. Alternative routes of administration for patients who are intubated without a nasogastric tube include crushing a tablet for absorption through the buccal mucosa or administration of a rectal suppository.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    should be deferred until after angiography, as many with MI and CS will require urgent coronary artery bypass surgery. When clopidogrel is deferred, we suggest the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors as soon as possible after the decision has been made to proceed to angiography. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'GP IIb/IIIa inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    infusion, especially in conjunction with reperfusion therapy, reduces mortality in acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. Even though heparin has not been evaluated in CS, there are compelling reasons that full-dose intravenous heparin therapy should be given. Patients in shock are in a low flow state with high fibrinogen concentrations. As a result, they are at risk for left ventricular and deep vein thrombosis. Heparin may also maintain coronary artery patency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors improve the outcome of patients with non-ST elevation ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    on patients with CS was evaluated in a post-hoc subgroup analysis from the PURSUIT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/21\">",
"     21",
"    </a>",
"    ]. Randomization to eptifibatide did not affect the incidence of shock. However, in patients who were treated with eptifibatide and developed shock, compared to those receiving placebo, a significantly reduced incidence of death at 30 days was noted (48 versus 58 percent in patients without an MI and 69 versus 85 percent in patients with an MI). A possible mechanism of benefit is relief of microvascular obstruction.",
"   </p>",
"   <p>",
"    Another possible mechanism for benefit is the possible therapeutic effect of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients with an STEMI and CS who undergo primary percutaneous coronary intervention (PCI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CS have been excluded from pivotal trials that have examined the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . In a recent small single center experience, outcomes were similar in patients who received bivalirudin and provisional GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor (n = 37) compared to patients (n = 49) treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Beta blockers and other negative inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that have negative inotropic activity should be avoided in patients with CS or \"pre-shock\" in which the cardiac output is severely diminished but hypotension has not yet developed. Included in this group are beta blockers and calcium channel blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. Evidence for this recommendation comes from the COMMIT trial in which randomization to early beta blockade was associated with a 30 percent higher occurrence of cardiogenic shock in patients over the age of 70, those with systolic BP &lt;120 mm Hg or presenting heart rate greater than 110 beats per minute, and those with Killip Class &gt;1. In addition, antiarrhythmic drugs with negative inotropic or vasodilating properties, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , bretylium, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , should be used with caution.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , although it has beta blocking properties, is the preferred antiarrhythmic agent when one is required for sustained ventricular or atrial tachyarrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vasopressors and inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt treatment of hypotension and hypoperfusion is essential to the management of CS. Both pharmacologic and nonpharmacologic methods of circulatory support are employed to reverse hypotension, maintain vital organ perfusion, and maintain coronary perfusion pressures as high as possible. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Mechanical support'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sympathomimetic inotropic and vasopressor agents remain the mainstay of first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       Norepinephrine",
"      </a>",
"      is a potent vasopressor with positive inotropic properties that may be used for rapid initial circulatory support for CS. The minimum required dose should be used.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       Dopamine",
"      </a>",
"      in alpha-agonist doses (greater than 15",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min). It also has positive inotropic effects, which may be beneficial but produces an undesirable elevation in pulmonary capillary wedge pressure (PCWP). The minimum required dose should be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    has often been",
"    <span class=\"nowrap\">",
"     chosen/recommended",
"    </span>",
"    before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    , and the latter used when the response to dopamine is inadequate, some evidence suggests that outcomes may be better with norepinephrine. In a trial of 1679 patients with circulatory shock due to varying etiologies (septic, hypovolemic, and CS) who were randomly assigned to initial therapy with either dopamine or norepinephrine, there was a trend toward higher rate of death at 28 days with dopamine and there were significantly more arrhythmias, predominantly atrial fibrillation. There was no difference in the treatment effect based on shock type, including in the subset of 280 patients with cardiogenic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient evidence upon which a firm recommendation for the choice of the first vasopressor in patients with cardiogenic shock can be made. Our experts suggest starting with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    , but emphasize that efforts should be made to minimize both the number of agents and their dose. In some patients measurement of hemodynamic parameters such as cardiac output and arterial pressure (as well as the calculation of systemic vascular resistance), may guide the choice of vasopressors and inotropes.",
"   </p>",
"   <p>",
"    In some patients, measurement of hemodynamic parameters such as cardiac output and arterial pressures (and calculation of systemic vascular resistance) may guide the choice of vasopressors and inotropes. However, there is no evidence that titrating medications based on hemodynamics improves outcomes.",
"   </p>",
"   <p>",
"    Unfortunately, increasing systemic vascular resistance (SVR) with vasopressors in patients who already have an elevated SVR induced by endogenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    and angiotensin II limits the improvement in cardiac output, increases cardiac work, and raises the PCWP. As a result, mechanical support devices are preferred, as soon as they can be instituted.",
"   </p>",
"   <p>",
"    A possible alternative is the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or a phosphodiesterase inhibitor, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , which are inotropic agents that also produce vasodilation. However, these drugs do not reverse the hypotension in post-MI shock, which, as noted above, is sometimes accompanied by vasodilation rather than vasoconstriction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used as first-line single therapy when hypotension is present, but can be given to less sick patients with a low cardiac index and high PCWP but no hypotension. An additive effect can be achieved by combining moderate dose dobutamine with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    . Milder cases (ie, nonhypotensive patients in low output state) can also be treated with dobutamine in combination with vasodilators (such as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ), which will further reduce both afterload and preload.",
"   </p>",
"   <p>",
"    Phosphodiesterase inhibitors have not been studied in patients with an acute MI and CS and are",
"    <strong>",
"     not",
"    </strong>",
"    recommended. The possible role of intravenous L-NMMA (tilarginine acetate), inhibitor of nitric oxide synthase that produces vasoconstriction, was evaluated in the TRIUMPH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/10\">",
"     10",
"    </a>",
"    ]. Enrollment was stopped prematurely based upon a prespecified futility analysis. There was no statistically significant difference in all-cause mortality at 30 days between treatment and placebo (48 and 42 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally begin therapy with a vasopressor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    ) in hypotensive patients with systemic hypoperfusion. The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    is limited to less sick patients with a low cardiac index, high PCWP, and borderline blood pressure without frank hypotension. An additive effect can be achieved by combining moderate dose dobutamine and norepinephrine or dopamine. Non-hypotensive patients in a low output state can also be treated with dobutamine plus a vasodilator (intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ). This combination will further reduce both afterload and preload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Differences compared to patients without shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the discussion above, the following summarizes potential differences in care compared to patients without CS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      should be held until after angiography.",
"     </li>",
"     <li>",
"      If used,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      should be used in lower doses.",
"     </li>",
"     <li>",
"      Drugs with negative inotropic properties such as beta blockers and calcium channel blockers should be avoided during the period of shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insertion of a balloon-tipped pulmonary artery (Swan-Ganz) catheter and an intraarterial blood pressure monitoring catheter are in general useful as part of the diagnostic evaluation of the patient with CS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Hemodynamic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reperfusion therapy should not be delayed for the placement of a pulmonary artery catheter. Hemodynamic monitoring is useful in patients with refractory shock despite revascularization.",
"   </p>",
"   <p>",
"    Repeated determination of hemodynamics is in general useful to guide therapeutic intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19,24,25\">",
"     19,24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of cardiac filling pressures so that hypovolemia and volume overload can be identified and corrected. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Volume management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Evaluation of the response of cardiac output to therapeutic interventions, including volume management, sympathomimetics, and mechanical support.",
"     </li>",
"     <li>",
"      Detection and quantification of intracardiac shunting in ventricular septal defect complicating acute MI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link&amp;anchor=H10#H10\">",
"       \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the interventricular septum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calculation of systemic vascular resistance and discrimination of vasoconstrictive from vasodilatory shock. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Volume management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia may be present, particularly in the setting of diuretic use or vomiting. Intravenous fluid replacement should be guided by measurement of the pulmonary capillary wedge pressure (PCWP), arterial oxygen saturation (SaO2), systemic arterial pressure, and cardiac output. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Hemodynamic monitoring'",
"    </a>",
"    above.) Each patient's optimal PCWP is the lowest value that results in the highest cardiac output as long as the SaO2 is above 90 percent. The usual value in CS is between 18 and 25 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An empiric intravenous volume challenge of 250 mL of isotonic saline can be given prior to right heart catheterization in patients with suspected CS when there is no evidence of pulmonary congestion on physical examination or chest x-ray and the patient is not in respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. Overly vigorous fluid challenges in patients with extensive left ventricular infarction, particularly older adults, will result in pulmonary edema and should be avoided.",
"   </p>",
"   <p>",
"    On the other hand, there are two settings in which more volume support is indicated: right ventricular shock due to a right ventricular MI, in which high filling pressures are required to maximize flow to the left ventricle; and the venodilation and hypotension that are common with inferior MI, but do not constitute a shock state. The diagnosis of right ventricular MI is suspected in patients with inferior MI, clear lung fields, and shock. It can also be confirmed by the use of right sided ECG leads. In patients with presumed right ventricular shock, vigorous IV fluid replacement is indicated if jugular (central) venous pressure is not elevated. An early echocardiogram can be performed in this setting to guide clinical management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with volume overload and cardiogenic pulmonary edema without hypotension may require therapy with diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , supplemental oxygen, and vasodilators. The management of this complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ventilatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilatory support may be required for several reasons in patients with CS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To protect the airway and maintain oxygen supply in patients with a deterioration in consciousness or cardiac arrest.",
"     </li>",
"     <li>",
"      To treat acute respiratory failure, most often due to cardiogenic pulmonary edema. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To raise the arterial pH in metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of mechanical ventilation may increase the likelihood of successful weaning from intra-aortic balloon pump (IABP) support. This was suggested by a report of 28 patients with strictly defined CS receiving inotropic medication and IABP counterpulsation; 10 patients were also supported with mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/27\">",
"     27",
"    </a>",
"    ]. A significantly larger proportion of ventilated patients were weaned from IABP (90 versus 44 percent) and discharged from the hospital (80 versus 28 percent).",
"   </p>",
"   <p>",
"    In selected patients who require mechanical ventilation, endotracheal intubation may not be necessary and a trial of noninvasive positive pressure ventilation is warranted (",
"    <a class=\"graphic graphic_table graphicRef59165 \" href=\"mobipreview.htm?9/17/9499\">",
"     table 3",
"    </a>",
"    ). This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal blood glucose target in patients with MI, including those who are critically ill, is unknown. The data addressing the issue of glucose targets during the acute phase of myocardial infarction, including very ill patients, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MECHANICAL SUPPORT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intraaortic balloon pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence does not support the routine use of an intraaortic balloon pump in most patients with acute MI complicated by cardiogenic shock (CS) in whom primary PCI is attempted or performed or in whom fibrinolytic therapy is administered. However, benefit may exist in patients with mechanical defects (such as mitral regurgitation or a ventricular septal defect) and selected other patients who are rapidly deteriorating. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the interventricular septum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link&amp;anchor=H17#H17\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Acute mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best evidence against the routine use of IABP for patient with MI comes from the IABP-SHOCK II trial in which 600 patients with CS complicating acute MI (STEMI and NSTEMI) were randomly assigned to the device or no device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/28\">",
"     28",
"    </a>",
"    ]. All patients were expected to undergo early revascularization (predominantly with PCI) and to receive best available medical care. At 30 days, there was no difference in the rate of all-cause mortality (39.7 versus 41.3 percent, respectively; relative risk 0.96, 95% CI 0.79-1.17). There were no significant differences in secondary end points such as length of stay in the intensive care unit, renal function, or the rates of major bleeding, peripheral ischemic complications, sepsis, or stroke. The results were largely consistent across all subgroups, although trends in favor of IABP use were noted for those without prior MI or hypertension.",
"   </p>",
"   <p>",
"    One weakness of the study was a high rate of crossover of patients in the control group to IABP for reasons other than the development of a mechanical complication (26 of 30 insertions were thought to be protocol violations). However, a per protocol adjusted analysis that excluded patients who crossed over came to the same conclusions. It is possible that rapidly deteriorating patients may not have been enrolled and if enrolled, crossed over; the study cohort may represent those who stabilized on",
"    <span class=\"nowrap\">",
"     vasopressor/inotropic",
"    </span>",
"    support. Thus, the trial results may not apply to severe shock with rapid deterioration. Further data and longer follow-up is needed to better understand subsets that may benefit from IABP.",
"   </p>",
"   <p>",
"    Two earlier observational studies support the findings in IABP-SHOCK II.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Registry of Myocardial Infarction (NRMI) 2 found no reduction in in-hospital mortality associated with the use of an IABP in patients undergoing primary percutaneous coronary intervention (PCI) for CS (47 versus 42 percent without IABP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/29\">",
"       29",
"      </a>",
"      ], although some benefit was found in hospitals with a higher rate of IABP use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"       \"Intraaortic balloon pump counterpulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 2009 meta-analysis of nine observational studies including over 10,000 patients with CS found no significant benefit with IABP in the entire cohort, but a significant decrease in 30 day mortality in patients treated with fibrinolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/31\">",
"       31",
"      </a>",
"      ]. However, this meta-analysis is limited due to selection bias and the lack of randomization of IABP in this setting. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Use with fibrinolysis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those patients with CS undergoing PCI in whom an IABP is chosen, the optimal timing of placement is unknown as the observational evidence is conflicting. In IABP SHOCK II, there was no difference in outcomes between those who received an IABP before or after PCI. In a study of 48 patients with MI and CS, a significantly lower in-hospital mortality at 30 days (19 versus 69 percent) was found in those who received the IABP before as opposed to after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/32\">",
"     32",
"    </a>",
"    ]. However, an earlier analysis from the SHOCK trial registry suggested that the mortality was similar whether IABP was placed before or after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Use with fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of IABP in MI patients treated with fibrinolytic therapy who will be transferred for possible revascularization is not well established, as there is little evidence that can be used to guide the formation of recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\", section on 'Primary failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies have suggested that the rate of clot dissolution with fibrinolysis in CS can be restored to normal levels if the blood pressure is raised by aggressive use of vasopressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/34\">",
"     34",
"    </a>",
"    ] or insertion of an IABP (",
"    <a class=\"graphic graphic_figure graphicRef59524 \" href=\"mobipreview.htm?20/2/20525\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/35\">",
"     35",
"    </a>",
"    ]. There are no randomized clinical data demonstrating the efficacy and safety of combined IABP and fibrinolysis in CS complicating MI. However, there is some evidence suggesting efficacy.",
"   </p>",
"   <p>",
"    The National Registry of Myocardial Infarction 2 evaluated 23,180 patients who had CS during hospitalization; an IABP, which was used in 31 percent of patients, was associated with a significantly lower in-hospital mortality in those who received fibrinolytic therapy (49 versus 67 percent without IABP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/29\">",
"     29",
"    </a>",
"    ]. A similar benefit from IABP combined with fibrinolytic therapy was noted in the SHOCK trial registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/33\">",
"     33",
"    </a>",
"    ] and the GUSTO-1 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/36\">",
"     36",
"    </a>",
"    ]. The potential for bias in these studies is great.",
"   </p>",
"   <p>",
"    Few MI patients with CS will present to hospitals where fibrinolysis will be administered instead of revascularization but where an IABP is available. For these uncommon patients whose hemodynamic parameters and clinical status are rapidly deteriorating while on vasopressor and inotropic support and who will be transferred for cardiac catheterization, our authors and reviewers have differing approaches, with some recommending placement of an IABP and others not. The decision to place an IABP or not should be made in consultation with physicians at the receiving cardiac catheterization laboratory. The decision should be included by the expertise of the team placing the IABP, potential delays in transfer, and patient-related factors such as risk of bleeding and quality of vascular access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other mechanical devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other circulatory support devices are sometimes used or are being investigated in patients with CS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link&amp;anchor=H6#H6\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\", section on 'Short-term VAD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular and biventricular assist devices. In the setting of CS, these surgically placed devices are usually placed as a bridge to transplantation in eligible patients in whom ventricular function is not expected to recover.",
"     </li>",
"     <li>",
"      Percutaneous left atrial-to-femoral arterial ventricular assist device. This device (Tandem Heart) is placed via the femoral vein and across the interatrial septum to provide temporary circulatory support while performing high-risk PCI or awaiting ventricular recovery.",
"     </li>",
"     <li>",
"      Percutaneous cardiopulmonary bypass support with use of an extracorporeal membrane oxygenator is utilized when oxygenation is severely impaired.",
"     </li>",
"     <li>",
"      Percutaneous transvalvular LVAD. This device (Impella LP 2.5) is placed via the femoral artery, retrograde across the aortic valve into the left ventricle. It has a microaxial pump that decompresses the left ventricle and delivers a maximum flow of 2.5",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      into the ascending aorta. In a multicenter observational registry of 120 patients with CS after acute myocardial infarction who received the Impella-2.5 device following initial IABP support, 30-day mortality was 64.2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/37\">",
"       37",
"      </a>",
"      ]. Without a compactor group, we do not know how this would compare to no device or to other devices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two small, randomized trials have compared a percutaneous left ventricular assist device (LVAD) to an IABP in patients with CS after an acute MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first study compared the LVAD (Tandem Heart) in 41 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/38\">",
"       38",
"      </a>",
"      ]. Although hemodynamic and metabolic parameters were more effectively reversed with the LVAD, complications such as severe bleeding and limb ischemia were more common. The mortality rates were similar, but this study was not powered to assess mortality.",
"     </li>",
"     <li>",
"      In the second study, 25 patients were randomly assigned to LVAD (Impella) or an IABP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/39\">",
"       39",
"      </a>",
"      ]. The LVAD was placed safely in all assigned patients and significantly improved hemodynamic parameters, such as cardiac index at 30 minutes to a greater extent than IABP (0.5 versus 0.1",
"      <span class=\"nowrap\">",
"       L/min/m",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"      Important outcomes such as death could not be meaningfully assessed due to the small sample size, but as noted above for the Tandem Heart study, mortality rates were similar for the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of these devices is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on STEMI, which recommended an IABP as a stabilizing measure in an acute MI in patients with CS that is not quickly reversed with pharmacologic therapy (",
"    <a class=\"graphic graphic_table graphicRef54567 \" href=\"mobipreview.htm?16/5/16476\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71542 \" href=\"mobipreview.htm?42/17/43291\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/40\">",
"     40",
"    </a>",
"    ]. No changes to this approach were made in the 2007 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/41\">",
"     41",
"    </a>",
"    ]. The 2008 European Society of Cardiology task force on the management of ST-segment elevation acute myocardial infarction made similar recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/42\">",
"     42",
"    </a>",
"    ]. The use of an IABP, in addition to assisting hemodynamic management, is an important measure to stabilize the patient to permit angiography and revascularization.",
"   </p>",
"   <p>",
"    Primary PCI in patients in CS should be performed with IABP support, and many feel strongly that this support should be instituted prior to the first coronary angiographic dye injection (",
"    <a class=\"graphic graphic_table graphicRef71542 \" href=\"mobipreview.htm?42/17/43291\">",
"     table 4",
"    </a>",
"    ). This regimen might allow the patient to tolerate the procedure better and has documented efficacy for reducing acute closure after PCI. Other experts recommend opening the culprit artery as soon as possible, and then placing an IABP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     REPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, there is evidence that the high mortality associated with CS has improved over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/5,7,9,43\">",
"     5,7,9,43",
"    </a>",
"    ]. This benefit is thought to be predominantly due to increased use of coronary reperfusion strategies, which, by restoring patency to the infarct-related artery, can limit infarct size, as well as interrupt the vicious spiral that characterizes CS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/5-7,12\">",
"     5-7,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the evidence of benefit for early reperfusion therapy has come from observations of patients with STEMI. However, in patients without shock, reperfusion with fibrinolytic therapy has not been shown to be of benefit in patients with NSTEMI. Therefore most of the discussion below is directed at patients with STEMI; for those patients in whom a diagnosis of NSTEMI with CS is made, we believe that early reperfusion with revascularization (PCI or CABG) is useful.",
"   </p>",
"   <p>",
"    Observational data suggest that an open infarct-related artery in patients with CS complicating an acute MI correlates strongly with in-hospital survival. In a report of 200 patients from Duke, for example, the in-hospital mortality was much lower in patients with a patent compared to a closed infarct-related artery (33 versus 75 percent); this relationship was independent of how patency was achieved (eg, spontaneous or pharmacologic fibrinolysis or mechanical intervention) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/44\">",
"     44",
"    </a>",
"    ]. Similar findings were noted in the SHOCK trial registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"     15",
"    </a>",
"    ]. In-hospital mortality was lower in patients with TIMI grade 3 (normal) flow (26 versus 47 percent with TIMI grade",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    [no or faint flow]).",
"   </p>",
"   <p>",
"    Coronary reperfusion can be achieved with fibrinolysis (in patients with STEMI), percutaneous coronary intervention (PCI) or emergency coronary artery bypass graft surgery (CABG). Outcomes are better when successful reperfusion can be delivered early in the course of MI.",
"   </p>",
"   <p>",
"    We support the approach to reperfusion recommended in the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation myocardial infarction (which was not changed in the 2007 update) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/45\">",
"     45",
"    </a>",
"    ]. This approach was refined in a 2008 publication and is presented in algorithmic form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited randomized data assessing the efficacy of fibrinolysis compared to either placebo or PCI in patients who have CS at presentation. The available studies have demonstrated some benefit of fibrinolysis compared to placebo, but superiority of PCI or CABG compared to fibrinolysis. Fibrinolysis is recommended if PCI is not possible or if it is delayed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 1994 meta-analysis from the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group found that, among patients with a systolic blood pressure &lt;100 mmHg and a heart rate &gt;100 beats per minute, fibrinolysis was associated with a 7 percent absolute reduction in mortality at one month compared to control (54 versus 61 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/46\">",
"     46",
"    </a>",
"    ]. The apparently limited efficacy of fibrinolysis may have reflected failure to augment coronary perfusion pressure during administration of the fibrinolytic agent. In animal studies, the rate of dissolution of a coronary artery thrombus by fibrinolytic therapy is markedly depressed when hypotension is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a post-hoc analysis of the SHOCK trial, the use of fibrinolytic therapy was associated with a significant reduction in mortality at 12 months (60 versus 78 percent without fibrinolysis) in the group assigned to medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the apparent benefit in those who did not receive immediate revascularization and the absence of adverse effects in those who underwent invasive procedures, fibrinolytic therapy should be given to patients who present to a facility without primary PCI or timely transfer for primary PCI capability, particularly those who present within three hours of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Use with fibrinolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data, derived only from subset analyses of major fibrinolytic therapy trials, evaluating the comparative efficacy of different fibrinolytic agents. There is no evidence to suggest greater benefit of one agent compared with another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/6,48\">",
"     6,48",
"    </a>",
"    ]. Thus, the choice of agent should probably not be different from patients without CS (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"mobipreview.htm?25/33/26140\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Late shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations on fibrinolysis were primarily made in patients who had CS at or soon after presentation. However, the majority of patients develop shock after initial emergency department presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/6,8,21,40,49\">",
"     6,8,21,40,49",
"    </a>",
"    ]. Such patients have a somewhat lower in-hospital mortality than those in CS on admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/40,49\">",
"     40,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Time of onset'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only role for fibrinolysis administered more than 12 to 24 hours after onset of an MI is if the development of late shock is thought to be due to recurrent coronary artery occlusion and if urgent angiography and revascularization cannot be performed; prompt transfer to a tertiary center with revascularization facilities should be arranged for patients in whom late shock is thought to be due to recurrent coronary artery occlusion, unless impossible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary percutaneous coronary intervention (PCI) is preferred to fibrinolysis for CS complicating acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/41,50-54\">",
"     41,50-54",
"    </a>",
"    ]. PCI is usually performed only on the infarct-related artery; however, some patients have undergone multivessel intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/55\">",
"     55",
"    </a>",
"    ]. The decision should be guided by the clinical profile of the patient, anatomic characteristics, operator experience, lack of response to PCI of the infarct-related artery, and documentation of hypokinesis in the remote zones.",
"   </p>",
"   <p>",
"    Initial experience with coronary intervention in CS was obtained in studies of the benefits of early angiography following fibrinolysis. Nonrandomized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/52\">",
"     52",
"    </a>",
"    ] and randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/53\">",
"     53",
"    </a>",
"    ] have shown benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     SHOCK trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of early revascularization in patients with CS were confirmed in the SHOCK trial, a randomized comparison of emergency revascularization versus a strategy of initial medical stabilization including fibrinolysis and IABP in patients with an ST elevation MI (or new left bundle branch block) and CS.",
"   </p>",
"   <p>",
"    The SHOCK trial included 302 patients with confirmed CS developing within 36 hours of an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/53\">",
"     53",
"    </a>",
"    ]. The patients were randomly assigned within 12 hours of the diagnosis of shock to emergency revascularization (CABG in 40 percent and PCI in 60 percent) within six hours of randomization or to initial medical stabilization.",
"   </p>",
"   <p>",
"    Almost half of the patients assigned to emergency revascularization had had prior fibrinolysis, and therefore underwent rescue PCI or CABG; 63 percent of patients in the medical arm also received fibrinolytic therapy. Late revascularization was performed in 25 percent of patients in the medical stabilization arm at a minimum of 54 hours after randomization at the discretion of the local physician. Intra-aortic balloon counterpulsation was utilized in 86 percent of patients in both groups.",
"   </p>",
"   <p>",
"    At 30 days, there was an insignificant 9 percent absolute difference in total mortality (primary end point) between the two treatment groups (47 versus 56 percent with initial medical therapy with fibrinolysis); the lack of significance could represent beta error since the trial was underpowered to detect such a difference. The benefit increased over time and became significant at six months. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Long-term outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients in CS on admission have a higher in-hospital mortality than the majority of patients who develop shock after hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/40,49\">",
"     40,49",
"    </a>",
"    ]. However, in the SHOCK trial and registry, patients in shock on admission derived the same in-hospital mortality benefit from emergency revascularization (60 versus 82 percent) as those who developed shock later (46 versus 62 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Late shock'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Determinants of outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical response to primary PCI is highly variable. While some patients improve rapidly after PCI, others show no immediate hemodynamic improvement, and a few transiently deteriorate after reperfusion is established, particularly if there is late reperfusion. This is also true for late reperfusion with fibrinolysis. Concurrent use of an IABP protects against sudden hemodynamic deterioration. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Intraaortic balloon pump'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Data from the nonrandomized SHOCK trial registry suggest that the in-hospital mortality after PCI is related to the degree of reperfusion achieved in the infarct related artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/56\">",
"     56",
"    </a>",
"    ]. Among 276 patients undergoing PCI, the mortality for TIMI grade 3 (normal), grade 2, or grade",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    flow was 33, 50, and 86 percent, respectively. A similar relationship to TIMI flow grade was noted in a report from the ALKK primary PCI registry in Germany (37, 66, and 78 percent in-hospital mortality, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time from symptom onset to PCI may be another determinant of outcome. In the ALKK report, the in-hospital mortality was 44 percent in patients receiving primary and rescue PCI as well as urgent CABG within three hours from symptom onset, 45 percent from three to six hours, 54 percent from 6 to 12 hours, and 58 percent from 12 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the benefits of primary PCI were seen in both early and late presenters in the SHOCK trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/53\">",
"     53",
"    </a>",
"    ]. As a result, late presenters should not be denied emergency revascularization based upon timing alone. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'SHOCK trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a prespecified subset analysis of the SHOCK trial, the benefit of revascularization on survival was limited to patients &lt;75 years old, but there were too few elderly patients in this subgroup to be confident of the observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/54\">",
"     54",
"    </a>",
"    ]. Subsequent studies, including the SHOCK registry, have found the same magnitude of benefit in patients &ge;75 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. At present no firm conclusion regarding the magnitude of benefit (or harm) can be made in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Use in left main stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the SHOCK trial registry, 16 percent of patients with CS had significant left main disease (although not necessarily left main occlusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"     15",
"    </a>",
"    ]. Although emergent CABG is a revascularization option, it appears to be seldom utilized in contemporary clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential efficacy of PCI in patients with CS and left main disease was suggested in an observational registry of unprotected left main stenosis; 40 patients with an acute MI (37 of whom had CS) underwent emergency PCI (17 with stenting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/59\">",
"     59",
"    </a>",
"    ]. The rate of in-hospital death (35 versus 70 percent) was lower in those who received a stent compared to primary balloon angioplasty alone. Stenting was also associated with a higher survival rate at 12 months (53 versus 35 percent). A much higher in-hospital mortality rate of 81 percent was noted after primary PCI among 80 patients with a left main stem infarct-related artery in the ALKK primary PCI registry in Germany [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=see_link\">",
"     \"Management of left main coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Coronary artery bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with CS after MI have significant left main or three vessel disease (16 and 53 percent, respectively, in the SHOCK trial registry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"     15",
"    </a>",
"    ]. In such patients, the ability to achieve complete revascularization makes CABG a potentially critical therapeutic strategy. A surgical approach also permits the correction of concomitant severe mitral regurgitation, which is often present. Pooled data on 370 patients in 22 studies revealed an in-hospital mortality rate of 36 percent when CABG was performed during the hospitalization for acute MI with CS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=see_link&amp;anchor=H2860987#H2860987\">",
"     \"Coronary artery bypass graft surgery after acute ST elevation myocardial infarction\", section on 'Cardiogenic shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relatively low mortality rate in these nonrandomized series may reflect a true benefit or selection bias, in which patients at lowest risk are selected for CABG. However, similar findings (41 percent overall mortality) were noted in the patients who underwent emergency CABG in the SHOCK trial within six hours of randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/53\">",
"     53",
"    </a>",
"    ]. Despite this benefit, CABG is underutilized in the community setting. In a review from the National Registry of Myocardial Infarction of 25,311 patients with CS seen from 1995 to 2004 in the United States, the overall rate of immediate CABG was stable at about 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     PCI versus CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative efficacy of PCI and CABG was evaluated in the 128 patients with predominant left ventricular failure who underwent emergency revascularization in the SHOCK trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/60\">",
"     60",
"    </a>",
"    ]. Not surprisingly, the 47 patients (37 percent) who underwent CABG were significantly more likely to have diabetes and three-vessel or left main disease; 85 percent of these patients received two or more grafts and 52 percent received three or more grafts. Despite the more extensive disease in the CABG group, overall survival was similar to PCI at 30 days (57 versus 56 percent with PCI) and one year (47 versus 52 percent). The similar outcomes, despite the worse disease in patients undergoing CABG, may reflect in part the higher rate of complete revascularization (87 versus 23 percent with PCI).",
"   </p>",
"   <p>",
"    In clinical practice, a combination of these two revascularization strategies is often indicated. This may involve emergent percutaneous recanalization of the infarct related artery in the catheterization laboratory followed by",
"    <span class=\"nowrap\">",
"     emergent/urgent",
"    </span>",
"    revascularization with CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations from population-based studies suggest that the results of the SHOCK trial itself can be applied to clinical practice. As an example, similar 30-day survival benefits with early revascularization were noted in the larger nonrandomized SHOCK trial registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/58,61\">",
"     58,61",
"    </a>",
"    ]. The outcome with revascularization was the same in men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=see_link\">",
"     \"Management of coronary heart disease in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observations were comparable in the review cited above from the National Registry of Myocardial Infarction (NRMI) of 25,311 patients with CS seen between 1995 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the short-term benefits, follow-up reports from the SHOCK trial demonstrated that the benefit of revascularization persists for many years. At one year, early revascularization was associated with a lower mortality rate (eg, 53 versus 66 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, the patients who were assigned to emergency revascularization were significantly more likely to remain stable after discharge (71 versus 44 percent at one year) and less likely to worsen or die after 30 days (15 versus 34 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality benefit persisted at six years (67 versus 80 percent with medical stabilization) (",
"    <a class=\"graphic graphic_figure graphicRef78579 \" href=\"mobipreview.htm?34/34/35375\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/64\">",
"     64",
"    </a>",
"    ]. The previously observed significant interaction between age and treatment effect was no longer evident on long-term follow-up.",
"   </p>",
"   <p>",
"    Evidence of long-term benefit was also suggested in a subset analysis from the GUSTO-I trial of over 39,000 patients who were alive at 30 days after an acute MI, 1306 of whom had been in CS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/65\">",
"     65",
"    </a>",
"    ]. Revascularization within 30 days was performed in 44 percent of the patients with CS; the one-year mortality in these patients was significantly lower than in those who were not revascularized (8 versus 15 percent, odds ratio 0.6 after adjusting for differences in baseline characteristics). Not surprisingly, the survivors of CS had higher one-year mortality than those without shock (12 versus 3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines for the management of patients with STEMI recommend primary PCI or emergent CABG in patients less than 75 years of age with an STEMI or MI with new or presumably new left bundle branch block who develop shock within 36 hours of MI, can be treated within 18 hours of the onset of shock, and are suitable for revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19,20,66\">",
"     19,20,66",
"    </a>",
"    ]. It is considered reasonable to perform primary PCI or emergent CABG in selected patients &ge;75 years of age who meet the same criteria and are suitable for revascularization.",
"   </p>",
"   <p>",
"    Fibrinolytic therapy (in the absence of contraindications) is given a strong recommendation in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for patients who are unsuitable for invasive therapy (because of age, comorbidities, or personal preference) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Fibrinolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy for the management of CS is characterized by an early revascularization strategy with adjunctive IABP support. Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Revascularization with either PCI or CABG is preferred to fibrinolytic therapy, if it can be performed in a timely manner (within 90 minutes from initial hospital presentation for PCI). This is consistent with the management of patients without CS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"       \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary PCI is preferred to CABG for patients with one- or two-vessel coronary disease and technically suitable lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/67\">",
"       67",
"      </a>",
"      ]. Immediate CABG may be considered for left main or severe three-vessel disease. If CABG cannot be performed, single-vessel or multivessel PCI may be attempted. CABG is the treatment of choice if there are associated mechanical complications.",
"     </li>",
"     <li>",
"      We suggest the prompt administration of fibrinolytic therapy if the PCI related delay is anticipated to exceed 60 minutes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the door-to-balloon time is anticipated to exceed 90 minutes. In addition we suggest fibrinolytic therapy for patients who are unsuitable for invasive therapy (because of age, comorbidities, or personal preference). This approach was given a class I recommendation in the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who appear to have successfully reperfused with fibrinolytic therapy and who no longer manifest CS, we suggest not taking the patient to the catheterization laboratory urgently, based on the evidence of harm with PCI soon after fibrinolysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link&amp;anchor=H7#H7\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Facilitated PCI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When fibrinolytic agents are given, they should be combined with vigorous vasopressor use and IABP (inserted cautiously to reduce the risk of bleeding) in an attempt to normalize coronary perfusion pressure. As mentioned above, fibrinolysis is relatively ineffective when administered to hypotensive patients (",
"      <a class=\"graphic graphic_figure graphicRef59524 \" href=\"mobipreview.htm?20/2/20525\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients admitted to hospitals without facilities for revascularization should be immediately transferred to a tertiary care center with such facilities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"       19",
"      </a>",
"      ]. Such patients can be treated with insertion of an IABP (if available) if there is a delay in transfer or the tertiary care center is far away. If there is an anticipated very long delay in transport for cardiac catheterization AND the risks of fibrinolysis are low AND the duration of MI symptoms is &lt;3 hours, we recommend rapid initiation of fibrinolytic therapy (&lt;30 minutes) prior to transfer.",
"     </li>",
"     <li>",
"      Patients who survive initial therapy that does not include emergency PCI or CABG should be referred for coronary angiography and potential revascularization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"       19",
"      </a>",
"      ]. This recommendation is based upon the high prevalence of a low left ventricular ejection fraction and three vessel or left main disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"       15",
"      </a>",
"      ], settings in which revascularization is associated with a long-term reduction in mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality in patients with cardiogenic shock (CS) complicating myocardial infarction (MI) approaches 50 percent, despite advances in therapeutic interventions such as the early use of percutaneous coronary intervention and improvements in medical care, particularly aggressive antithrombotic therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This high mortality can be lowered with further improvements in the speed with which reperfusion is delivered, and vigilant observation of those hospitalized patients with MI at risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a summary of our approach to the treatment of patients with CS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An emergency echocardiogram should be performed to determine the etiology of shock in the absence of a large MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/37/35418/abstract/19\">",
"     19",
"    </a>",
"    ]. Echocardiography can be useful to estimate left atrial pressure as well as to identify the etiology of shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link&amp;anchor=H694484061#H694484061\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamic monitoring, including pulmonary artery catheterization, may be useful to guide optimal medical management, particularly when the diagnosis is in doubt. Monitoring is also useful in distinguishing vasoconstrictive from vasodilatory shock. However, placement of a pulmonary artery catheter should not delay transferring the patient to the catheterization laboratory. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Hemodynamic monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy of CS consists of early identification, optimally before frank hypotension is present, and rapid stabilization with correction of metabolic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for the use of antiplatelet agents in patients with MI are given separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with CS in whom revascularization is planned, we recommend not giving a thienopyridine until after diagnostic coronary angiography (and PCI is to be performed) and adding a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as early as possible after diagnosis (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). This recommendation is based upon the fact that a higher percentage of patients with CS complicating MI will require CABG compared to those without and the potential benefits for glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    agents with PCI in the highest risk subsets. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Oral antiplatelet therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend withholding beta blockers and calcium channel blockers in patients with CS (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Beta blockers and other negative inotropes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend vasopressors for patients with cardiogenic shock (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Although there is no definitive evidence of the superiority of one vasopressor over another, we suggest beginning with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Vasopressors and inotropes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     IABP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the use of an intraaortic balloon pump (IABP) in patients with acute MI and cardiogenic shock are as follows (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Intraaortic balloon pump'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom mechanical complications (eg, acute mitral regurgitation or rupture of the ventricular septum) are not present and for whom revascularization is planned, we suggest not placing an IABP as a routine strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      However, for such patients whose hemodynamic parameters and clinical status are rapidly deteriorating while on vasopressor and inotropic support, we suggest placement of an IABP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Deterioration is considered present when the systolic blood pressure is persistently below 80 mmHg, there is a fall urine output or a worsening of mentation, the arterial oxygen saturation is falling, or cardiac arrhythmias (including heart block or ventricular tachycardia or fibrillation) develop or worsen.",
"     </li>",
"     <li>",
"      The role of IABP is not well studied in the uncommon patient treated with fibrinolytic therapy whose hemodynamic parameters and clinical status are rapidly deteriorating while on vasopressor and inotropic support and for whom transfer to a facility capable of performing urgent revascularization is planned. Our authors and reviewers have differing approaches, with some recommending placement of an IABP before transfer and other not. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Use with fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CS complicating MI should undergo an attempt at reperfusion. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Reperfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations for the use of reperfusion therapy in patients with MI complicated by CS are similar to those for most patients with MI and differ principally in the level of evidence (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ST elevation MI, we recommend revascularization as opposed to fibrinolytic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This recommendation requires that diagnostic coronary angiography be performed within 90 minutes of initial hospital presentation. For those patients who cannot undergo timely coronary angiography, we recommend fibrinolytic therapy rather than no immediate reperfusion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with one or two vessel disease who do not have mechanical complications, we recommend percutaneous coronary intervention (PCI) of the infarct related artery as opposed to CABG (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with three vessel disease or left main disease who do not have mechanical complications (such as acute mitral regurgitation or rupture of either the ventricular septal or free walls), we suggest immediate PCI as opposed to CABG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In many cases it may be appropriate to prefer CABG based on factors such as the likelihood of successful revascularization with PCI, the extent of disease, the skill",
"      <span class=\"nowrap\">",
"       level/experience",
"      </span>",
"      of the PCI team, or the availability of immediate CABG.",
"     </li>",
"     <li>",
"      For patients with mechanical complications, we recommended immediate CABG and attempt at repair of the mechanical defect as opposed to PCI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with non-ST elevation MI, we recommend that revascularization be performed as soon as possible as opposed to either fibrinolytic therapy or no reperfusion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/1\">",
"      Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/2\">",
"      Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009; 119:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/3\">",
"      Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991; 325:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/4\">",
"      Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/5\">",
"      Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction. Am Heart J 2001; 141:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/6\">",
"      Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/7\">",
"      Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/8\">",
"      Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/9\">",
"      Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/10\">",
"      TRIUMPH Investigators, Alexander JH, Reynolds HR, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/11\">",
"      Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/12\">",
"      Meinertz T, Kasper W, Schumacher M, Just H. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988; 62:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/13\">",
"      Hasdai D, Holmes DR Jr, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J 1999; 138:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/14\">",
"      Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/15\">",
"      Wong SC, Sanborn T, Sleeper LA, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/16\">",
"      Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003; 42:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/17\">",
"      Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/18\">",
"      Ortolani P, Marzocchi A, Marrozzini C, et al. Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. Eur Heart J 2006; 27:1550.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/21\">",
"      Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/22\">",
"      Bonello L, De Labriolle A, Roy P, et al. Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock. Am J Cardiol 2008; 102:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/23\">",
"      De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/24\">",
"      Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998; 32:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/25\">",
"      Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/26\">",
"      Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000; 36:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/27\">",
"      Kontoyannis DA, Nanas JN, Kontoyannis SA, et al. Mechanical ventilation in conjunction with the intra-aortic balloon pump improves the outcome of patients in profound cardiogenic shock. Intensive Care Med 1999; 25:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/28\">",
"      Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/29\">",
"      Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001; 141:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/30\">",
"      Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 2003; 108:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/31\">",
"      Sjauw KD, Engstr&ouml;m AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 2009; 30:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/32\">",
"      Abdel-Wahab M, Saad M, Kynast J, et al. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2010; 105:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/33\">",
"      Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/34\">",
"      Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 20:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/35\">",
"      Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994; 23:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/36\">",
"      Anderson RD, Ohman EM, Holmes DR Jr, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/37\">",
"      Lauten A, Engstr&ouml;m AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/38\">",
"      Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/39\">",
"      Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/40\">",
"      Jeger RV, Harkness SM, Ramanathan K, et al. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. Eur Heart J 2006; 27:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/41\">",
"      O'Neill WW. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? J Am Coll Cardiol 1992; 19:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/42\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/43\">",
"      Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus&auml;rzte (ALKK). Eur Heart J 2004; 25:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/44\">",
"      Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992; 20:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/45\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/46\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/47\">",
"      French JK, Feldman HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/48\">",
"      Hasdai D, Holmes DR Jr, Topol EJ, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J 1999; 20:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/49\">",
"      Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/50\">",
"      Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991; 18:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/51\">",
"      Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol 1998; 31:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/52\">",
"      Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/53\">",
"      Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/54\">",
"      Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/55\">",
"      Mylotte D, Morice MC, Eltchaninoff H, et al. Primary percutaneous coronary intervention in patients with acute myocardial infarction, resuscitated cardiac arrest, and cardiogenic shock: the role of primary multivessel revascularization. JACC Cardiovasc Interv 2013; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/56\">",
"      Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001; 141:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/57\">",
"      Lim HS, Farouque O, Andrianopoulos N, et al. Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. JACC Cardiovasc Interv 2009; 2:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/58\">",
"      Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003; 24:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/59\">",
"      Marso SP, Steg G, Plokker T, et al. Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the ULTIMA experience). Unprotected Left Main Trunk Intervention Multi-center Assessment. Am J Cardiol 1999; 83:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/60\">",
"      White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 2005; 112:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/61\">",
"      Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/62\">",
"      Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. J Am Coll Cardiol 2001; 38:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/63\">",
"      Sleeper LA, Ramanathan K, Picard MH, et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005; 46:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/64\">",
"      Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/65\">",
"      Berger PB, Tuttle RH, Holmes DR Jr, et al. One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. Circulation 1999; 99:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/66\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/37/35418/abstract/67\">",
"      Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107:2998.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-1FFB8D27E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35418=[""].join("\n");
var outline_f34_37_35418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Temporal trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predictors of mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - STEMI versus NSTEMI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Coronary anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Echocardiographic predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Symptom onset to reperfusion time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      After successful reperfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oral antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Beta blockers and other negative inotropes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Differences compared to patients without shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Volume management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ventilatory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MECHANICAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intraaortic balloon pump",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Use with fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other mechanical devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      REPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Late shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - SHOCK trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Use in left main stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Coronary artery bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - PCI versus CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Population-based studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      IABP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Reperfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/83\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/2/20525\" title=\"figure 1\">",
"      BP and efficacy of thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/34/35375\" title=\"figure 2\">",
"      Survival revasc vs med rx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/44/4812\" title=\"table 1\">",
"      Rx options cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/5/16476\" title=\"table 2\">",
"      ACC AHA Rx cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/17/9499\" title=\"table 3\">",
"      Indicator success NPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/17/43291\" title=\"table 4\">",
"      ACC AHA IABP in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/33/26140\" title=\"table 5\">",
"      Thrombolytic regimens STEMI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=related_link\">",
"      Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_37_35419="Estimating energy expenditure";
var content_f34_37_35419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised World Health Organization equations for estimating energy expenditure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Step 1: Estimate basal metabolic rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Men 18 to 30 years = (0.0630 x actual weight in kg + 2.8957) x 240 kcal/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Men 31 to 60 years = (0.0484 x actual weight in kg + 3.6534) x 240 kcal/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Women 18 to 30 years = (0.0621 x actual weight in kg + 2.0357) x 240 kcal/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Women 31 to 60 years = (0.0342 x actual weight in kg + 3.5377) x 240 kcal/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Step 2: Determine activity factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Activity level",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Activity factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low (sedentary)",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermediate (some regular exercise)",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High (regular activity or demanding job)",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Step 3: Estimate total energy expenditure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Total energy expenditure = Basal metabolic rate x activity factor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35419=[""].join("\n");
var outline_f34_37_35419=null;
var title_f34_37_35420="Risk factors fracture after transplant";
var content_f34_37_35420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for fracture after transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pre transplant factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Low bone mineral density related to underlying disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatic osteodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteoporosis of end-stage pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal osteodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pre-existing history of fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Poor nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lifestyle factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Post transplant factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immunosuppressive regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcineurin inhibitors (cyclosporine, tacrolimus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Poor nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lifestyle factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inactivity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Maalouf NM and Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90:2456.",
"      <br>",
"       Rakel A, Sheehy O, Rahme E, et al. Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study. J Bone Miner Res 2007; 22:1878.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35420=[""].join("\n");
var outline_f34_37_35420=null;
var title_f34_37_35421="History physical exam A";
var content_f34_37_35421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    History and physical examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 600px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35421=[""].join("\n");
var outline_f34_37_35421=null;
var title_f34_37_35422="Number of hospital discharges with diabetic ketoacidosis";
var content_f34_37_35422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Number (in thousands) of hospital discharges with diabetic ketoacidosis as first-listed diagnosis, United States, 1980-2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The number of hospital discharges with diabetic ketoacidosis (DKA) as the first-listed diagnosis increased between 1980 and 2005, with about 62,000 discharges in 1980 with DKA as the first-listed diagnosis and about 120,000 in 2005.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention: Diabetes Data &amp; Trends. Retreived from file://www.cdc.gov/diabetes/statistics/dkafirst/fig1.htm on March 1, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35422=[""].join("\n");
var outline_f34_37_35422=null;
var title_f34_37_35423="ESC cardioversion strategy";
var content_f34_37_35423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    ESC cardioversion strategy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 542px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cardioversion of haemodynamically stable AF, the role of TOE-guided cardioversion, and subsequent anticoagulation strategy.",
"    <div class=\"footnotes\">",
"     AF: atrial fibrillation; DCC: direct current cardioversion; LA: left atrium; LAA: left atrial appendage; OAC: oral anticoagulant; SR: sinus rhythm; TOE: transoesophageal echocardiography.",
"     <br>",
"      * Anticoagulation should normally be continued for 4 weeks after a cardioversion attempt except when AF is recent onset and no risk factors are present.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Long-term OAC if stroke risk factors and/or risk of AF recurrence/presence of thrombus.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369, by permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_37_35423=[""].join("\n");
var outline_f34_37_35423=null;
             